```
=> file zcaplus
FILE 'ZCAPLUS' ENTERED AT 08:45:09 ON 25 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 25 Jun 2008  VOL 148 ISS 26
FILE LAST UPDATED: 24 Jun 2008  (20080624/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L15
L10          19 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  BROOKINGS D?/AU
L11        7394 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  DAVIS J?/AU
L12          26 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  LANGHAM B?/AU
L13          11 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L10 AND (L11 OR L12)
L14           9 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L11 AND L12
L15          11 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  (L13 OR L14)


=> file medline embase biosis wpix
FILE 'MEDLINE' ENTERED AT 08:45:23 ON 25 JUN 2008

FILE 'EMBASE' ENTERED AT 08:45:23 ON 25 JUN 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 08:45:23 ON 25 JUN 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'WPIX' ENTERED AT 08:45:23 ON 25 JUN 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

=> d stat que L16
L10          19 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  BROOKINGS D?/AU
L11        7394 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  DAVIS J?/AU
L12          26 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  LANGHAM B?/AU
L13          11 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L10 AND (L11 OR L12)
L14           9 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L11 AND L12
L15          11 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  (L13 OR L14)
L16          13 SEA L15


=> dup rem L15 L16
FILE 'ZCAPLUS' ENTERED AT 08:45:33 ON 25 JUN 2008
```

FILE 'MEDLINE' ENTERED AT 08:45:33 ON 25 JUN 2008

FILE 'EMBASE' ENTERED AT 08:45:33 ON 25 JUN 2008

FILE 'BIOSIS' ENTERED AT 08:45:33 ON 25 JUN 2008

FILE 'WPIX' ENTERED AT 08:45:33 ON 25 JUN 2008

PROCESSING COMPLETED FOR L15
PROCESSING COMPLETED FOR L16
L17 12 DUP REM L15 L16 (12 DUPLICATES REMOVED)
ANSWERS '1-11' FROM FILE ZCAPLUS
ANSWER '12' FROM FILE BIOSIS

=> d ibib abs L17 1-11; d iall L17 12

L17 ANSWER 1 OF 12 ZCAPLUS DUPLICATE 1
ACCESSION NUMBER: 2008:223924 ZCAPLUS Full-text
DOCUMENT NUMBER: 148:285173
TITLE: Fused thiophene derivatives as MEK inhibitors and their preparation, pharmaceutical compositions and use in the treatment of inflammatory, autoimmune, cardiovascular, proliferative and nociceptive conditions
INVENTOR(S): Laing, Victoria Elizabeth; Brookings, Daniel Christopher; Carbery, Rachel Jane; Gascon Simorte, Jose Miguel; Hutchings, Martin Clive; Langham, Barry John; Lowe, Martin Alexander
PATENT ASSIGNEE(S): Ucb Pharma S.A., Belg.
SOURCE: PCT Int. Appl., 123pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020206	A2	20080221	WO 2007-GB3114	20070815
WO 2008020206	A3	20080424		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: GB 2006-16214 A 20060815
OTHER SOURCE(S): MARPAT 148:285173

GI



I II

AB A series of 4,5,6,7-tetrahydrothieno[2,3-c]azepin-8-one derivs. of formula I and analogs thereof, which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncol.) and nociceptive conditions. Compds. of formula I wherein Z is NHCO and derivs., NHCS and derivs., NHC=NH and derivs., CH2CO, CH2CS, CH2C=NH and derivs., etc.; R1 and R2 are independently H, (un)substituted C1-6 alkyl, (un)substituted C3-7 cycloalkyl, (un)substituted (hetero)aryl, etc.; R3 is H, C1-6 alkyl, (un)substituted C3-7 heterocycloalkenyl, CN, CO2H, CHO, acyl, CONH2 and derivs., etc.; R4a and R4b are independently Hm halo, CN, No2, C1-6 alkyl, CF3, etc.; R5 is halo, NO2, CN, C1-6 alkyl, C2-6 alkynyl, etc.; and their pharmaceutically acceptable salts and solvates thereof, are claimed. Example compound II was prepared by a general method (procedure given). All the invention compds. were evaluated for their MEK inhibitory activity.

L17 ANSWER 2 OF 12 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2007:873398 ZCAPLUS Full-text
DOCUMENT NUMBER: 147:235147
TITLE: Preparation of thienopyridines as MEK kinase inhibitors
INVENTOR(S): Hutchings, Martin Clive; Archibald, Sarah Catherine; Brookings, Daniel Christopher; Davis, Jeremy Martin; Johnson, James Andrew; Langham, Barry John; Neuss, Judi Charlotte
PATENT ASSIGNEE(S): UCB Pharma S.A., Belg.
SOURCE: PCT Int. Appl., 62pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007088345	A1	20070809	WO 2007-GB310	20070130

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,

RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2006-1962 A 20060131
OTHER SOURCE(S): MARPAT 147:235147
GI



I

AB Title compds. [I; R1 = H, halo, alkyl; R2 = halo, alkyl; R3 = H, cyano, CO2Ra, CONRbRC, CON(ORb)RC; Ra = alkyl; Rb = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, etc.; Rc = H, alkyl, hydroxyalkyl; NRbRc = azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, homopiperidinyl, homomorpholinyl, homopiperazinyl], were prepared Thus, NaH was added portionwise to a mixture of 2-fluoro-4-iodoisothiocyanatobenzene (preparation given) and Et 2-chloropyridin-3-ylacetate in Me2SO followed by heating at 70° for 3 h and standing overnight to give 48% Et 2-[(2-fluoro-4-iodophenyl)amino]thieno[2,3-b]pyridine-3-carboxylate. I inhibited human MEK with IC50 ≤10 μM.
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 12 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2007:79608 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:317142
TITLE: Novel nucleotide triphosphates as potent P2Y2 agonists
AUTHOR(S): Brookings, Daniel; Davenport, Richard J.; Davis, Jeremy; Galvin, Frances C. A.; Lloyd, Steve; Mack, Stephen R.; Owens, Ray; Sabin, Verity; Wynn, Joanne
CORPORATE SOURCE: Granta Park, UCB-Group, Cambridge, CB1 6GS, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(2), 562-565
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:317142
AB The synthesis and P2Y2 activities of a novel series of nucleoside triphosphates are described. Many of these compds. were potent agonists of the P2Y2 receptor.
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 12 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2004:1154721 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:93796

TITLE: Preparation of thienopyridone derivatives as p38 MAPK inhibitors

INVENTOR(S): Brookings, Daniel Christopher; Davis, Jeremy Martin; Langham, Barry John

PATENT ASSIGNEE(S): Celltech R & D Limited, UK

SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113348	A1	20041229	WO 2004-GB2644	20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249498	A1	20041229	AU 2004-249498	20040618
CA 2528603	A1	20041229	CA 2004-2528603	20040618
EP 1638979	A1	20060329	EP 2004-742997	20040618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2007516162	T	20070621	JP 2006-516453	20040618
US 20060247269	A1	20061102	US 2006-561050	20060629

PRIORITY APPLN. INFO.:

GB 2003-14490	A	20030620
GB 2003-29495	A	20031219
WO 2004-GB2644	W	20040618

OTHER SOURCE(S): MARPAT 142:93796

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X = covalent bond, NH or N(alkyl); Y = C(O) or S(O)2; A = (CH2)q; B = (CH2)m; n = 0 or 1; m = 1-3; p = 0-4; q = 0-2; R = (un)substituted OH, alkoxy or amino; L = O, S, S(O), S(O)2 or CH2, CHR or CR2, NH or N(alkyl); ALK1 = alkylene; Cy1 = (un)substituted (hetero)cycle or (hetero)aryl; Ar = (un)substituted (hetero)aryl; or salts, solvates, hydrates and N-oxides thereof] were prepared as p38 MAPK inhibitors. For example, II was synthesized in several steps from Et 3-bromo-6-oxo-7- phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate (preparation given), via amination with 2,4-difluoroaniline, ester hydrolysis, carboxy group activation with pentafluorophenol and coupling with cis-2- aminocyclopentanol hydrochloride. Example compds. had IC50 values of around 1 μM and below for human p38α kinase. Therefore, I and pharmaceutical compns. thereof are useful for the treatment and/or prevention of immune or inflammatory disorders.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 12 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 2004:1154720 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:93795
TITLE: Preparation of thienopyridone derivatives as p38α kinase inhibitors
INVENTOR(S): Brookings, Daniel Christopher; Davis, Jeremy Martin; Langham, Barry John
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113347	A1	20041229	WO 2004-GB2621	20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249495	A1	20041229	AU 2004-249495	20040618
CA 2528602	A1	20041229	CA 2004-2528602	20040618
EP 1641804	A1	20060405	EP 2004-742976	20040618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010653	A	20060704	BR 2004-10653	20040618
CN 1809575	A	20060726	CN 2004-80017320	20040618
JP 2007516161	T	20070621	JP 2006-516443	20040618
MX 2005PA13227	A	20060309	MX 2005-PA13227	20051206
IN 2005DN05823	A	20080201	IN 2005-DN5823	20051214
NO 2006000279	A	20060320	NO 2006-279	20060119
US 20070099894	A1	20070503	US 2006-561052	20061010

PRIORITY APPLN. INFO.:			GB 2003-14492	A 20030620
			GB 2003-29485	A 20031219
			WO 2004-GB2621	W 20040618

OTHER SOURCE(S): CASREACT 142:93795; MARPAT 142:93795
GI



AB Title compds. I [Y = linking group CO, SO2; n = 0-1; m, p = 1-4; R1 = OH, alkylene-OH, alkoxy, etc.; Alk1 = alkylene; Cyl = cycloaliph., aromatic, heteroarom., etc.; Ar = (un)substituted (hetero)aromatic, etc.] are prepared For instance, 3-Bromo-7-phenyl-2-[[(2R)-2-[(tetrahydro-2H-pyran-2-yl)oxy)methyl]pyrrolidin-1-yl]carbonyl]thieno[2,3-b]pyridin-6(7H)-one (preparation given) is coupled to 2,4-difluoroaniline (PhMe, Cs2CO3, BINAP, Pd2(dba)3, reflux 48 h) and the resulting product deprotected with HCl to give II. All compds. inhibit p38 kinase with IC50 of 1 μM or less. I are useful for the treatment and/or prevention of immune or inflammatory disorders.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 12 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2004:308438 ZCAPLUS Full-text

DOCUMENT NUMBER: 140:321242

TITLE: Preparation of pyrrolo[3,2-b]pyridines as p38 kinase inhibitors

INVENTOR(S): Brookings, Daniel Christopher; Cubbon, Rachel Jane; Davis, Jeremy Martin; Langham, Barry John

PATENT ASSIGNEE(S): Celltech R & D Limited, UK

SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031188	A1	20040415	WO 2003-GB4214	20030930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500844	A1	20040415	CA 2003-2500844	20030930
AU 2003271870	A1	20040423	AU 2003-271870	20030930
EP 1549648	A1	20050706	EP 2003-753708	20030930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006504712	T	20060209	JP 2004-540940	20030930
US 20060122212	A1	20060608	US 2005-529413	20050623
PRIORITY APPLN. INFO.:			GB 2002-22743 A	20021001
			WO 2003-GB4214 W	20030930

OTHER SOURCE(S): MARPAT 140:321242

GI



I



II

AB Title compds. I [A = (un)substituted N, C; Ra = H, halo, etc.; X, Y = N or (un)substituted C; L = C(O), C(S), (un)substituted C; n = 0-1; Alk1 = (unsubstituted)(hetero)aliphatic chain; L1 = bond, linker atom/group; Cy1 = (un)substituted cycloaliph., etc.; Ar = (hetero)aromatic, etc. with specific exceptions] are prepared For instance, 1-Benzenesulfonyl-4-phenyl-1,4-dihydro-5H-pyrrolo[3,2-b]pyridin-5-one (preparation given) is treated with NaOH (2M, 2 h) and the resulting product alkylated with benzyl chloride (THF, NaH) to give II. Example compds. have IC50 values of around 2 pM and below for p38 kinase and are useful for the treatment of immune or inflammatory disorders.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 12 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 2004:143162 ZCAPLUS Full-text
DOCUMENT NUMBER: 140:181432
TITLE: Preparation of bicyclic heteroaromatic compounds as p38 kinase inhibitors
INVENTOR(S): Brookings, Daniel Christopher; Davis, Jeremy Martin; Langham, Barry John
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014920	A1	20040219	WO 2003-GB3501	20030811

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2495518	A1	20040219	CA 2003-2495518		20030811
AU 2003252990	A1	20040225	AU 2003-252990		20030811
EP 1539769	A1	20050615	EP 2003-784288		20030811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005537300	T	20051208	JP 2004-527055		20030811
US 20060025428	A1	20060202	US 2005-524199		20050728
PRIORITY APPLN. INFO.:			GB 2002-18800	A	20020813
			WO 2003-GB3501	W	20030811

OTHER SOURCE(S): MARPAT 140:181432

GI



I



II

AB Title compds. I [A = N, (un)substituted CH, dashed line is a double bond; A = (un)substituted NH, CH2, dashed line is a single bond; X = O, S, (un)substituted NH, S(O), SO2; Y = N, (un)substituted CH; Alk = (un)substituted aliphatic, heteroaliph.; n = 0, 1; Ar = (un)substituted aromatic, heteroarom.; L = atom, alkylene, heteroalkylene; L1 = bond, linker atom, linker group; Cy = H, (un)substituted cycloaliph, polycycloaliph., heterocyclic, polyheterocyclic, aromatic, heteroarom.; R = H, CN, (un)substituted alkyl,CO2H, CONH2], especially 6-oxo-6,7-dihydrothieno[2,3-b]pyridine derivs., which are inhibitors of p38 kinase of use in the treatment and/or prevention of immune or inflammatory disorders (no data) were prepared Thus, II [R1 = NHCH2Ph, r2 = Ph] was prepared from 2-chloronicotinonitrile and HSCH2CO2Et via II [R1 = Br, R2 = H] by treatment with PhB(OH)2 and PhCH2NH2.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 12 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 8

ACCESSION NUMBER: 2004:2888 ZCAPLUS Full-text
DOCUMENT NUMBER: 140:59658
TITLE: Preparation of arylamine substituted bicyclic hetero-aromatic compounds as p38 kinase inhibitors
INVENTOR(S): Brookings, Daniel Christopher; Davis, Jeremy Martin; Langham, Barry John
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 174 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO	2004000846	A1	20031231	WO	2003-GB2667		20030620
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
CA	2487718	A1	20031231	CA	2003-2487718		20030620
AU	2003253087	A1	20040106	AU	2003-253087		20030620
BR	2003011842	A	20050315	BR	2003-11842		20030620
EP	1551848	A1	20050713	EP	2003-760802		20030620
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
CN	1671715	A	20050921	CN	2003-818371		20030620
JP	2005530838	T	20051013	JP	2004-515043		20030620
NZ	537740	A	20060331	NZ	2003-537740		20030620
MX	2004PA12746	A	20050323	MX	2004-PA12746		20041215
NO	2005000306	A	20050316	NO	2005-306		20050119
ZA	2005000524	A	20060830	ZA	2005-524		20050119
US	20060004025	A1	20060105	US	2005-518725		20050526
PRIORITY APPLN. INFO.:				GB	2002-14268	A	20020620
				WO	2003-GB2667	W	20030620

OTHER SOURCE(S): MARPAT 140:59658
GI



I

AB Bicyclic heteroarom. derivs. I; where the dashed line joining A and C(Ra) is present and represents a bond and A is a -N= atom or a -C(Rb)= group, or the dashed line is absent and A is a -N(Rb)-, or -C(Rb)(Rc)- group; X is an -O-, -S- or substituted nitrogen atom or a -S(O)-, -S(O2)- or -NH- group; Y is a nitrogen or substituted carbon atom or a -CH = group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or hetero-aliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cyclo-aliphatic, poly-cyclo-aliphatic, hetero-cyclo-aliphatic, poly-hetero-cyclo-aliphatic, aromatic or hetero-aromatic group; Ar is an optionally substituted aromatic or heteroarom. group; and the remaining substituents are defined in the specification. The compds. are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders. Thus, 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-N-pyrrolidin-3-yl-6,7- dihydrothieno[2,3-b]pyridine-2-carboxamide was prepared as a p38 kinase inhibitor. In the p38 inhibitor assays described above compds. of the invention have IC50 values of around 1 μM and below. The compds. of the invention are clearly potent inhibitors of p38 kinase, especially p38α kinase.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 12 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 9
ACCESSION NUMBER: 2003:434554 ZCAPLUS Full-text
DOCUMENT NUMBER: 139:22224
TITLE: Preparation of pyridine and pyrimidine derivatives as p38α kinase inhibitors
INVENTOR(S): Davis, Jeremy Martin; Langham, Barry John; Naik, Manisha; Brookings, Daniel Christopher; Cubbon, Rachel Jane; Franklin, Richard Jeremy
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045941	A1	20030605	WO 2002-GB5196	20021120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002339185	A1	20030610	AU 2002-339185	20021120
EP 1448555	A1	20040825	EP 2002-777562	20021120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20050080258	A1	20050414	US 2004-495885	20040803
US 7323464	B2	20080129		
PRIORITY APPLN. INFO.:			GB 2001-27929 A	20011121
			WO 2002-GB5196 W	20021120

OTHER SOURCE(S): MARPAT 139:22224
GI



I

AB Title compds. I [X = N, (un)substituted CH; Y = O, S, S(O), SO2, (un)substituted CH2, NH; when R3R4 = O, S, Y = (un)substituted CH2, NH; L1 = covalent bond, linker atom or group; Alk = (un)substituted aliphatic,

heteroaliph.; p = 0, 1; n = 0-3; when n = 0, Y = (un)substituted CH2; Ar = (un)substituted aromatic, heteroarom.; m = 0-3; q = 0-2; R1 = H, halogen, CN, NO2, (un)substituted cycloaliph., polycycloaliph., heterocycloaliph., aromatic, heteroarom; when L1 = bond and p = 0, R1 ≠ H, halogen, CN, NO2; R2 = H, halogen, CN, (un)substituted alkyl, OH, SH, CO2H; R3, R4 = H, R5; R3R4 = O, S; R5 = H, O, S, (un)substituted alkyl, OH, SH, CN,CO2H] were prepared for use as p38α kinase inhibitors, useful in the treatment of immune or inflammatory disorders. Thus, PhCHBrCO2Me was cyclized with H2NCH2CH2NH2 to give 3-phenyl-2-piperazinone which was treated with 2,4-dichloropyrimidine and 3-F3CC6H4CH2NH2 to give 3-phenyl-4-[2-(3-trifluoromethylbenzylamino)pyrimidin-4-yl] piperazin-2-one.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 12 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 10
ACCESSION NUMBER: 2003:319905 ZCAPLUS Full-text
DOCUMENT NUMBER: 138:321293
TITLE: Preparation of bicyclic oxopyridine and oxopyrimidine derivatives as potent selective inhibitors of p38 kinase
INVENTOR(S): Davis, Jeremy Martin; Brookings, Daniel Christopher; Langham, Barry John
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003033502	A1	20030424	WO 2002-GB4680	20021016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2462147	A1	20030424	CA 2002-2462147	20021016
AU 2002336172	A1	20030428	AU 2002-336172	20021016
AU 2002336172	B2	20070913		
EP 1438313	A1	20040721	EP 2002-770072	20021016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
HU 2004001718	A2	20041228	HU 2004-1718	20021016
JP 2005505627	T	20050224	JP 2003-536241	20021016
CN 1604901	A	20050406	CN 2002-825094	20021016
NZ 532713	A	20051028	NZ 2002-532713	20021016
MX 2004PA03450	A	20040716	MX 2004-PA3450	20040413
IN 2004DN00970	A	20050401	IN 2004-DN970	20040413
ZA 2004002803	A	20060628	ZA 2004-2803	20040413
NO 2004001975	A	20050716	NO 2004-1975	20040513
US 20040254200	A1	20041216	US 2004-492466	20040720
US 7176215	B2	20070213		

PRIORITY APPLN. INFO.: GB 2001-24848 A 20011016

WO 2002-GB4680 W 20021016

OTHER SOURCE(S): MARPAT 138:321293

GI



AB Bicyclic oxopyridine and oxopyrimidine derivs. (shown as I and II, resp. e.g. Et 6-oxo-3,7-diphenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate; the dashed line = an optional bond; A = N, N(Rb), C(Rb) or C(Rb)(RC); Ra, Rb and Rc = H or an optionally substituted C1-6alkyl; X = O, S, NH or substituted N; each Y = N, CH or substituted C; n = 0-1; Alk1 = optionally substituted aliphatic or heteroaliph. chain; L1 i= covalent bond or a linker atom or group; Cyl = H or optionally substituted cycloaliph., polycycloaliph., heterocycloaliph., polyheterocycloaliph., aromatic or heteroarom. group; Ar = optionally substituted aromatic or heteroarom. group) and the salts, solvates, hydrates and N-oxides thereof are described. The compds. are potent inhibitors of p38 kinase and are use in the prophylaxis or treatment of p38 kinase mediated diseases or disorders, such as rheumatoid arthritis. In the p38 inhibitor assay compds. of the invention have IC50 values of .apprx.30 μM and below. The more active compds. have IC50 values of .apprx.500 nM and below. The compds. of the invention are clearly potent inhibitors of p38 kinase, especially p38α kinase. Although the methods of preparation are not claimed, 17 example prepns. of intermediates and 129 example prepns. of I/II are included.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 12 ZCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:673573 ZCAPLUS Full-text

TITLE: Aminothienopyridinone derivatives as p38 MAP kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S): Davis, Jeremy Martin; Brookings, Daniel Christopher; Langham, Barry John; Hutchings, Martin Clive

PATENT ASSIGNEE(S): UCB Pharma, S.A., Belg.

SOURCE: PCT Int. Appl., 37pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008064829	A2	20080605	WO 2007-EP10189	20071123
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,				

KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2006-23955 A 20061130
EP 2007-1807 A 20070127

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to 3-aminothienopyridinone derivs. of formula I, to processes for preparing them, to pharmaceutical compns. containing them and to their use as pharmaceuticals. Compds. of formula I wherein R1 and R2 are independently C1-3 alkyl, halo and OH; m and n are independently 1-3; R3R4 taken together to form (un)substituted 4- to 6-membered non-aromatic heterocyle; and their pharmaceutically acceptable salts, stereoisomers, geometrical isomers, enantiomers and diastereoisomers thereof, are claimed. Example compound II was prepared by N-arylation of 3-bromo-7-(2,6-difluorophenyl)-2-({(2R)-2-[(tetrahydro-2H-pyran-2- yloxy)methyl]pyrrolidin-1-yl}carbonyl)thieno[2,3-b]pyridin-6(7H)-one with 2-amino-6-picoline. All the invention compds. were evaluated for their p38 MAP kinase inhibitory activity. From the assay, it was determined that II exhibited the IC50 values of 15 - 30 nm against p38α MAP kinase inhibitor.

L17 ANSWER 12 OF 12 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
ACCESSION NUMBER: 2007:180162 BIOSIS Full-text
DOCUMENT NUMBER: PREV200700174392
TITLE: Bicyclic oxopyridine and oxopyrimidine derivatives.
AUTHOR(S): Anonymous; Davis, Jeremy Martin [Inventor]; Brookings, Daniel Christopher [Inventor]; Langham, Barry John [Inventor]
CORPORATE SOURCE: Wokingham, UK
ASSIGNEE: Celltech RandD Limited
PATENT INFORMATION: US 07176215 20070213
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (FEB 13 2007)
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 7 Mar 2007
Last Updated on STN: 7 Mar 2007
ABSTRACT:Compounds of formulae (la) and (lb) are described: in which the dashed line represents an optional bond; A is a -Nbox drawings double horizontal atom or a -N(R-b)-, -C(R-b)box drawings double horizontal or -C(R-b)(R-C)- group;

R-a, R(b)and R(c)is each independently a hydrogen atom or an optionally substituted C(1-6)alkyl group; X is an -O- or -S- atom or -NH- group or substituted N atom; each Y is independently a N atom or CH group or substituted C atom; n is zero or the integer 1; Alk(1)is an optionally substituted aliphatic or heteroaliphatic chain L(1)is a covalent bond or a linker atom or group; Cy(1)is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof; The compounds are potent inhibitors of p38 kinase and are use in the prophylaxis or treatment of p38 kinase mediated diseases or disorders, such as rheumatoid arthritis

NAT. PATENT. CLASSIF.:514300000

CONCEPT CODE: Pathology - Therapy 12512
Bones, joints, fasciae, connective and adipose tissue - Pathology 18006
Pharmacology - General 22002
Pharmacology - Connective tissue, bone and collagen-acting drugs 22012
Pharmacology - Immunological processes and allergy 22018
Immunology - Immunopathology, tissue immunology 34508
Allergy 35500

INDEX TERMS: Major Concepts
Pharmacology

INDEX TERMS: Diseases
rheumatoid arthritis: immune system disease, joint disease, connective tissue disease, drug therapy
Arthritis, Rheumatoid (MeSH)

INDEX TERMS: Chemicals & Biochemicals
bicyclic oxopyridine derivatives: enzyme inhibitor-drug, antiarthritic-drug, immunologic-drug; bicyclic oxopyrimidine derivatives: enzyme inhibitor-drug, antiarthritic-drug, immunologic-drug

```
=> file registry
FILE 'REGISTRY' ENTERED AT 08:46:11 ON 25 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 JUN 2008  HIGHEST RN 1030103-54-8
DICTIONARY FILE UPDATES:  23 JUN 2008  HIGHEST RN 1030103-54-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Uploading L1.str
```






```
chain nodes :
10  12  13  14  15
ring nodes :
1  2  3  4  5  6  7  8  9
chain bonds :
2-10  7-14  8-12  12-13  14-15
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9
exact/norm bonds :
1-2  1-6  2-3  2-10  3-4  4-5  5-6  5-7  6-9  7-8  7-14  8-9  8-12  12-13  14-15



Connectivity :
10:1 E exact RC ring/chain  13:1 E exact RC ring/chain
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
```

```
12:CLASS  13:CLASS  14:CLASS  15:Atom
Generic attributes :
15:
Saturation             : Unsaturated
```

```
=> file zcaplus
FILE 'ZCAPLUS' ENTERED AT 08:46:14 ON 25 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 25 Jun 2008  VOL 148 ISS 26
FILE LAST UPDATED: 24 Jun 2008  (20080624/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L4
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L3          375 SEA FILE=REGISTRY SSS FUL L1
L4            7 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L3


=> file beilstein
FILE 'BEILSTEIN' ENTERED AT 08:46:33 ON 25 JUN 2008
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
```

FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.
*** FILE CONTAINS 10.322,808 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
separate documents and can not be searched together in one query.
Reaction data for BEILSTEIN compounds may be displayed
immediately with the display codes PRE (preparations) and REA
(reactions). A substance answer set retrieved after the search
for a chemical name, a compounds with available reaction
information by combining with PRE/FA, REA/FA or more generally
with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
between a BEILSTEIN compound and belonging reactions. For mo
detailed reaction searches BRNs can be searched as reaction
partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

```
*********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.               *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE  *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE         *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                       *
* FOR PRICE INFORMATION SEE HELP COST                               *
*********************************************************************
```

>>> Price change as of January 1st, 2008: Connect Time and Structure
Search fees re-introduced. See NEWS and HELP COST <<<

```
=> d stat que L6
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L6            3 SEA FILE=BEILSTEIN SSS FUL L1

100.0% PROCESSED     161 ITERATIONS                          3 ANSWERS
SEARCH TIME: 00.00.06


=> file wpix
FILE 'WPIX' ENTERED AT 08:46:42 ON 25 JUN 2008
```

FILE LAST UPDATED: 24 JUN 2008 <20080624/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE: 200840 <200840/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.1 million chemical structures in DCR <<<

>>> IPC Reform backfile reclassifications have been loaded to the end of March 2008. No update date (UP) has been created for the reclassified documents, but they can be identified by 20060101/UPIC and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC, 20071130/UPIC and 20080401/UPIC.
ECLA reclassifications to April and US national classifications to the end of January 2008 have also been loaded. Update dates 20080401/UPEC and /UPNC have been assigned to these. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0710.pdf

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

>>> Please note that the COPYRIGHT notification has changed <<<

'BIX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d stat que L9
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L8 21 SEA FILE=WPIX SSS FUL L1
L9 5 SEA FILE=WPIX ABB=ON PLU=ON L8/DCR

=> dup rem L4 L6 L9
DUPLICATE IS NOT AVAILABLE IN 'BEILSTEIN'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
FILE '2CAPLUS' ENTERED AT 08:46:52 ON 25 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'BEILSTEIN' ENTERED AT 08:46:52 ON 25 JUN 2008

FILE 'WPIX' ENTERED AT 08:46:52 ON 25 JUN 2008

PROCESSING COMPLETED FOR L4
PROCESSING COMPLETED FOR L6
PROCESSING COMPLETED FOR L9
L18 10 DUP REM L4 L6 L9 (5 DUPLICATES REMOVED)
ANSWERS '1-7' FROM FILE ZCAPLUS
ANSWERS '8-10' FROM FILE BEILSTEIN

=> d ibib abs hitstr L18 1-7; d ide allref L18 8-10

L18 ANSWER 1 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2005:409526 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:463710
TITLE: Preparation of thieno[2,3-b]pyridinone derivatives as kinase, especially p38 MAP kinase, inhibitors useful in the treatment of and/or prevention of immune or inflammatory disorders
INVENTOR(S): Alexander, Rikki Peter; Davis, Jeremy Martin; Hutchings, Martin Clive; Laing, Victoria Elizabeth; Trevitt, Graham Peter
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 181 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042540	A1	20050512	WO 2004-GB4490	20041022
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285752	A1	20050512	AU 2004-285752	20041022
CA 2540881	A1	20050512	CA 2004-2540881	20041022
EP 1680429	A1	20060719	EP 2004-769004	20041022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007509123	T	20070412	JP 2006-536178	20041022
US 20070078131	A1	20070405	US 2006-576731	20060420
PRIORITY APPLN. INFO.:			GB 2003-24902	A 20031024
			GB 2003-29490	A 20031219
			GB 2004-2918	A 20040210
			GB 2004-16934	A 20040729

WO 2004-GB4490 W 20041022

OTHER SOURCE(S): MARPAT 142:463710

GI



I



II

AB Title compds. I [wherein R1 = (un)substituted (C3-7 cycloalkyl)methyl, hetero/aryl; R2 = H, NO2, CN, CO2H and derivs., NH2 and derivs., etc.; R3 = (un)substituted hetero/aryl; and their pharmaceutically acceptable salts] were prepared as p38 MAP kinase inhibitors for treating and/or preventing immune or inflammatory disorders. For example, II was prepared by reacting Et 3-bromo-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2- carboxylate (preparation given) with 3-methylbenzaldehyde and oxidation with MnO2. I are potent inhibitors of p38 MAP kinase (IC50 around 2 μM and below), especially p38α kinase.

IT 660398-63-0P, Ethyl 3-[hydroxy(phenyl)methyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 660398-64-1P, Ethyl 3-[(hydroxy)(6-methylpyridin-2-yl)methyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 660398-65-2P, Ethyl 3-[(hydroxy)(3-methylphenyl)methyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 660398-68-5P, Ethyl 7-(cyclopropylmethyl)-3-[(hydroxy)(phenyl)methyl]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 660398-72-1P, Ethyl 3-[(3-chlorophenyl)(hydroxy)methyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 851747-26-7P, Ethyl 3-[(4-fluoro-3-methylphenyl)(hydroxy)methyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 851747-33-6P, Ethyl 3-[(6-methylpyridin-2-yl)carbonyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 851747-34-7P, 3-[(6-Methylpyridin-2-yl)carbonyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylic acid 851747-40-5P, Ethyl 3-[(hydroxy)(3-trifluoromethylphenyl)methyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 851747-41-6P, Ethyl 6-oxo-7-phenyl-3-[3-(trifluoromethyl)benzoyl]-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 851747-42-7P, 6-Oxo-7-phenyl-3-[3-(trifluoromethyl)benzoyl]-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylic acid 851747-93-8P, Ethyl 3-[(hydroxy)(phenyl)methyl]-6-oxo-7-

(pyridin-3-yl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 851747-95-9P, Ethyl 3-benzoyl-6-oxo-7-(pyridin-3-yl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 851748-00-6P, Ethyl 3-[(hydroxy)(phenyl)methyl]-7-(4-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 851748-02-8P, Ethyl 3-benzoyl-7-(4-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 851748-04-0P, 3-Benzoyl-7-(4-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thienopyridinones as p38 MAP kinase inhibitors
useful in the treatment of and/or prevention of immune or inflammatory disorders)

RN 660398-63-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-(hydroxyphenylmethyl)-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 660398-64-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[hydroxy(6-methyl-2-pyridinyl)methyl]-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 660398-65-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[hydroxy(3-methylphenyl)methyl]-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 660398-68-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-(cyclopropylmethyl)-6,7-dihydro-3-(hydroxyphenylmethyl)-6-oxo-, ethyl ester (CA INDEX NAME)



RN 660398-72-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-chlorophenyl)hydroxymethyl]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 851747-26-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)hydroxymethyl]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 851747-33-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[(6-methyl-2-pyridinyl)carbonyl]-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 851747-34-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[(6-methyl-2-pyridinyl)carbonyl]-6-oxo-7-phenyl- (CA INDEX NAME)



RN 851747-40-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[hydroxy[3-(trifluoromethyl)phenyl]methyl]-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 851747-41-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-[3-(trifluoromethyl)benzoyl]-, ethyl ester (CA INDEX NAME)



RN 851747-42-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-[3-

(trifluoromethyl)benzoyl]- (CA INDEX NAME)



RN 851747-93-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-(hydroxyphenylmethyl)-6-oxo-7-(3-pyridinyl)-, ethyl ester (CA INDEX NAME)



RN 851747-95-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-benzoyl-6,7-dihydro-6-oxo-7-(3-pyridinyl)-, ethyl ester (CA INDEX NAME)



RN 851748-00-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-(hydroxyphenylmethyl)-7-(4-methylphenyl)-6-oxo-, ethyl ester (CA INDEX NAME)



RN 851748-02-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-benzoyl-6,7-dihydro-7-(4-methylphenyl)-6-oxo-, ethyl ester (CA INDEX NAME)



RN 851748-04-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-benzoyl-6,7-dihydro-7-(4-methylphenyl)-6-oxo- (CA INDEX NAME)



IT 851750-29-3P, Ethyl 3-(3-methylbenzoyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 851750-31-7P, 3-(3-Methylbenzoyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylic acid 851750-47-5P, Ethyl 3-benzoyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 851750-49-7P, 3-Benzoyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylic acid 851751-02-5P, Ethyl 3-benzoyl-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 851751-12-7P, Ethyl 3-(3-chlorobenzoyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-

2-carboxylate 851751-22-9P, Ethyl 3-(4-fluoro-3-methylbenzoyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(p38α kinase inhibitor; preparation of thienopyridinones as p38 MAP kinase inhibitors useful in the treatment of and/or prevention of immune or inflammatory disorders)

RN 851750-29-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-(3-methylbenzoyl)-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 851750-31-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-(3-methylbenzoyl)-6-oxo-7-phenyl- (CA INDEX NAME)



RN 851750-47-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-benzoyl-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 851750-49-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-benzoyl-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 851751-02-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-benzoyl-7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 851751-12-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-(3-chlorobenzoyl)-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 851751-22-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-(4-fluoro-3-methylbenzoyl)-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



IT 851750-39-5P, 3-(3-Methylbenzoyl)-6-oxo-7-phenyl-6,7-

dihydrothieno[2,3-b]pyridine-2-carboxamide 851750-41-9P, 2-(Azetidin-1-ylcarbonyl)-3-(3-methylbenzoyl)-7-phenylthieno[2,3-b]pyridin-6(7H)-one 851750-85-1P, 3-Benzoyl-N-methyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 851750-87-3P, 2-(Azetidin-1-ylcarbonyl)-3-benzoyl-7-phenylthieno[2,3-b]pyridin-6(7H)-one 851750-89-5P, 3-Benzoyl-N-(1,1-dimethyl-2-hydroxyethyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 851750-91-9P, 3-Benzoyl-N,N-dimethyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 851750-93-1P, 3-Benzoyl-2-[[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one 851750-94-2P, 3-Benzoyl-2-(morpholin-4-ylcarbonyl)-7-phenylthieno[2,3-b]pyridin-6(7H)-one 851750-96-4P, 3-Benzoyl-7-phenyl-2-(pyrrolidin-1-ylcarbonyl)thieno[2,3-b]pyridin-6(7H)-one 851751-00-3P, 3-Benzoyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 851751-10-5P, 3-(3-Chlorobenzoyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 851751-18-3P, 3-(2,4-Difluorobenzoyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 851751-20-7P, 3-(4-Fluoro-3-methylbenzoyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 851751-28-5P, 3-(3-Chloro-4-fluorobenzoyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(p38α kinase inhibitor; preparation of thienopyridinones as p38 MAP kinase inhibitors useful in the treatment of and/or prevention of immune or inflammatory disorders)

RN 851750-39-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-3-(3-methylbenzoyl)-6-oxo-7-phenyl- (CA INDEX NAME)



RN 851750-41-9 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-(1-azetidinylcarbonyl)-3-(3-methylbenzoyl)-7-phenyl- (CA INDEX NAME)



RN 851750-85-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-benzoyl-6,7-dihydro-N-methyl-6-oxo-

7-phenyl- (CA INDEX NAME)



RN 851750-87-3 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-(1-azetidinylcarbonyl)-3-benzoyl-7-phenyl- (CA INDEX NAME)



RN 851750-89-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-benzoyl-6,7-dihydro-N-(2-hydroxy-1,1-dimethylethyl)-6-oxo-7-phenyl- (CA INDEX NAME)



RN 851750-91-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-benzoyl-6,7-dihydro-N,N-dimethyl-6-oxo-7-phenyl- (CA INDEX NAME)



RN 851750-93-1 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-benzoyl-2-[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 851750-94-2 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-benzoyl-2-(4-morpholinylcarbonyl)-7-phenyl- (CA INDEX NAME)



RN 851750-96-4 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-benzoyl-7-phenyl-2-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)



RN 851751-00-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-benzoyl-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 851751-10-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-(3-chlorobenzoyl)-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 851751-18-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-(2,4-difluorobenzoyl)-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 851751-20-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-(4-fluoro-3-methylbenzoyl)-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 851751-28-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-(3-chloro-4-fluorobenzoyl)-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2004:1154721 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:93796
TITLE: Preparation of thienopyridone derivatives as p38 MAPK inhibitors
INVENTOR(S): Brookings, Daniel Christopher; Davis, Jeremy Martin; Langham, Barry John
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113348	A1	20041229	WO 2004-GB2644	20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249498	A1	20041229	AU 2004-249498	20040618
CA 2528603	A1	20041229	CA 2004-2528603	20040618
EP 1638979	A1	20060329	EP 2004-742997	20040618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2007516162	T	20070621	JP 2006-516453	20040618
US 20060247269	A1	20061102	US 2006-561050	20060629
PRIORITY APPLN. INFO.:			GB 2003-14490 A	20030620
			GB 2003-29495 A	20031219
			WO 2004-GB2644 W	20040618

OTHER SOURCE(S): MARPAT 142:93796
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X = covalent bond, NH or N(alkyl); Y = C(O) or S(O)2; A = (CH2)q; B = (CH2)m; n = 0 or 1; m = 1-3; p = 0-4; q = 0-2; R = (un)substituted OH, alkoxy or amino; L = O, S, S(O), S(O)2 or CH2, CHR or CR2, NH or N(alkyl); ALK1 = alkylene; Cyl = (un)substituted (hetero)cycle or (hetero)aryl; Ar = (un)substituted (hetero)aryl; or salts, solvates, hydrates and N-oxides thereof] were prepared as p38 MAPK inhibitors. For example, II was synthesized in several steps from Et 3-bromo-6-oxo-7- phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate (preparation given), via amination with 2,4-difluoroaniline, ester hydrolysis, carboxy group activation with pentafluorophenol and coupling with cis-2- aminocyclopentanol hydrochloride. Example compds. had IC50 values of around 1 μM and below for human p38α kinase. Therefore, I and pharmaceutical compns. thereof are useful for the treatment and/or prevention of immune or inflammatory disorders.

IT 816464-58-1P, 3-[(4-Fluoro-3-methylphenyl)amino]-7-phenyl-2-[(piperidin-4-yl)carbonyl]thieno[2,3-b]pyridin-6(7H)-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(inhibitor; preparation of thienopyridone derivs. as p38 MAPK inhibitors)

RN 816464-58-1 ZCAPLUS

CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-7-phenyl-2-(4-piperidinylcarbonyl)- (CA INDEX NAME)



IT 639481-27-9P 816464-52-5P 816464-53-6P 816464-54-7P, 3-[(2,4-Difluorophenyl)amino]-N-((1S,2S)-2-hydroxycyclopentyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 816464-55-8P, 3-[(2,4-Difluorophenyl)amino]-N-((1R,2R)-2-hydroxycyclopentyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 816464-56-9P 816464-57-0P, 3-Anilino-7-phenyl-2-(piperidin-4-ylcarbonyl)thieno[2,3-b]pyridin-6(7H)-one 816464-59-2P, N-(Azetidin-3-yl)-3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 816464-60-5P 816464-61-6P 816464-62-7P 816464-63-8P, 3-[(2,4-Difluorophenyl)amino]-6-oxo-7-phenyl-N-(piperidin-4-yl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 816464-64-9P, 3-[(2,4-Difluorophenyl)amino]-N-(1-methylpiperidin-4-yl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 816464-65-0P, 3-[(2,4-Difluorophenyl)amino]-7-phenyl-2-[(piperidin-4-yl)carbonyl]thieno[2,3-b]pyridin-6(7H)-one 816464-66-1P, 3-[(6-Methylpyridin-2-yl)amino]-7-phenyl-2-[(piperidin-4-yl)carbonyl]thieno[2,3-b]pyridin-6(7H)-one 816464-67-2P, 3-[(4-Fluoro-3-methylphenyl)amino]-2-[(1-

methylpiperidin-4-yl)carbonyl]-7-phenylthieno[2,3-b]pyridin-6(7H)-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(inhibitor; preparation of thienopyridone derivs. as p38 MAPK inhibitors)

RN 639481-27-9 ZCAPLUS

CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-N-3-pyrrolidinyl- (CA INDEX NAME)



RN 816464-52-5 ZCAPLUS

CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-N-[(1R,2S)-2-hydroxycyclopentyl]-6-oxo-7-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 816464-53-6 ZCAPLUS

CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-N-[(1R,2R)-2-hydroxycyclopentyl]-6-oxo-7-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 816464-54-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-N-[(1S,2S)-2-hydroxycyclopentyl]-6-oxo-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816464-55-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-N-[(1R,2R)-2-hydroxycyclopentyl]-6-oxo-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816464-56-9 ZCAPLUS

CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816464-57-0 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-phenyl-3-(phenylamino)-2-(4-piperidinylcarbonyl)- (CA INDEX NAME)



RN 816464-59-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, N-3-azetidinyl-3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 816464-60-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-N-(3S)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816464-61-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-N-[(3S)-1-methyl-3-pyrrolidinyl]-6-oxo-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816464-62-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-N-[(3R)-1-methyl-3-pyrrolidinyl]-6-oxo-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816464-63-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-N-4-piperidinyl- (CA INDEX NAME)



RN 816464-64-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-N-(1-methyl-4-piperidinyl)-6-oxo-7-phenyl- (CA INDEX NAME)



RN 816464-65-0 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-7-phenyl-2-(4-piperidinylcarbonyl)- (CA INDEX NAME)



RN 816464-66-1 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(6-methyl-2-pyridinyl)amino]-7-phenyl-2-(4-piperidinylcarbonyl)- (CA INDEX NAME)



RN 816464-67-2 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-2-[(1-methyl-4-piperidinyl)carbonyl]-7-phenyl- (CA INDEX NAME)



IT 639479-24-6P, Ethyl 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 639482-02-3P, Pentafluorophenyl 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 639482-11-4P, Pentafluorophenyl 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 639482-17-0P, Benzyl 3-[[[3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl]carbonyl]amino]pyrrolidine-1-carboxylate 639504-79-3P, Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 816424-65-4P , Lithium 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 816424-66-5P, Lithium 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 816464-41-2P, Tert-Butyl (3R)-3-[[[3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl]carbonyl]amino]pyrrolidine-1-carboxylate 816464-45-6P, Tert-Butyl (3S)-3-[[[3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl]carbonyl]amino]pyrrolidine-1-carboxylate 816464-46-7P, Tert-Butyl 4-[[[3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl]carbonyl]amino]piperidine-1-carboxylate 816464-50-3P, Benzyl 4-[[3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl]carbonyl]piperidine-1-carboxylate 816464-51-4P, Benzyl 4-[[3-[(6-methylpyridin-2-yl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl]carbonyl]piperidine-1-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thienopyridone derivs. as p38 MAPK inhibitors)
RN 639479-24-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639482-02-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, 2,3,4,5,6-pentafluorophenyl ester (CA INDEX NAME)



RN 639482-11-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, 2,3,4,5,6-pentafluorophenyl ester (CA INDEX NAME)



RN 639482-17-0 ZCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl]carbonyl]amino]-, phenylmethyl ester (CA INDEX NAME)



RN 639504-79-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 816424-65-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, lithium salt (1:1) (CA INDEX NAME)



RN 816424-66-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, lithium salt (1:1) (CA INDEX NAME)



RN 816464-41-2 ZCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816464-45-6 ZCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816464-46-7 ZCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl]carbonyl]amino]-,

1,1-dimethylethyl ester (CA INDEX NAME)



RN 816464-50-3 ZCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl]carbonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 816464-51-4 ZCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6,7-dihydro-3-[(6-methyl-2-pyridinyl)amino]-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl]carbonyl]-, phenylmethyl ester (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2004:1154720 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:93795

TITLE: Preparation of thienopyridone derivatives as p38α kinase inhibitors

INVENTOR(S): Brookings, Daniel Christopher; Davis, Jeremy Martin; Langham, Barry John

PATENT ASSIGNEE(S): Celltech R & D Limited, UK

SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113347	A1	20041229	WO 2004-GB2621	20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249495	A1	20041229	AU 2004-249495	20040618
CA 2528602	A1	20041229	CA 2004-2528602	20040618
EP 1641804	A1	20060405	EP 2004-742976	20040618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010653	A	20060704	BR 2004-10653	20040618
CN 1809575	A	20060726	CN 2004-80017320	20040618
JP 2007516161	T	20070621	JP 2006-516443	20040618
MX 2005PA13227	A	20060309	MX 2005-PA13227	20051206
IN 2005DN05823	A	20080201	IN 2005-DN5823	20051214
NO 2006000279	A	20060320	NO 2006-279	20060119
US 20070099894	A1	20070503	US 2006-561052	20061010

PRIORITY APPLN. INFO.:			GB 2003-14492	A 20030620
			GB 2003-29485	A 20031219
			WO 2004-GB2621	W 20040618

OTHER SOURCE(S): CASREACT 142:93795; MARPAT 142:93795

GI



I



II

AB Title compds. I [Y = linking group CO, SO2; n = 0-1; m, p = 1-4; R1 = OH, alkylene-OH, alkoxy, etc.; Alk1 = alkylene; Cy1 = cycloaliph., aromatic, heteroarom., etc.; Ar = (un)substituted (hetero)aromatic, etc.] are prepared For instance, 3-Bromo-7-phenyl-2-[[(2R)-2-[((tetrahydro-2H-pyran-2-yl)oxy)methyl]pyrrolidin-1-yl]carbonyl]thieno[2,3-b]pyridin-6(7H)-one (preparation given) is coupled to 2,4-difluoroaniline (PhMe, Cs2CO3, BINAP, Pd2(dba)3, reflux 48 h) and the resulting product deprotected with HCl to give II. All compds. inhibit p38 kinase with IC50 of 1 μM or less. I are useful for the treatment and/or prevention of immune or inflammatory disorders.

IT 816423-93-5P 816423-94-6P 816423-95-7P
816423-96-8P 816423-97-9P 816423-98-0P
816423-99-1P 816424-00-7P 816424-01-8P
816424-02-9P 816424-03-0P 816424-04-1P
816424-05-2P 816424-06-3P 816424-07-4P
816424-08-5P 816424-09-6P 816424-10-9P
816424-11-0P 816424-12-1P 816424-13-2P
816424-14-3P 816424-15-4P 816424-16-5P
816424-17-6P 816424-18-7P 816424-19-8P
816424-20-1P 816424-21-2P 816424-22-3P
816424-23-4P 816424-24-5P 816424-25-6P
816424-26-7P 816424-27-8P 816424-28-9P
816424-29-0P 816424-31-4P 816424-32-5P
816424-33-6P 816424-34-7P 816424-35-8P
816424-36-9P 816424-37-0P 816424-38-1P
816424-39-2P 816424-40-5P 816424-41-6P
816424-42-7P 816424-43-8P 816424-44-9P
816424-45-0P 816424-46-1P 816424-47-2P
816424-48-3P 816424-49-4P 816424-50-7P
816424-51-8P 816424-52-9P 816424-53-0P
816424-54-1P 816424-55-2P 816424-56-3P
816424-57-4P 816424-58-5P 816424-59-6P
816424-60-9P 816424-61-0P 816424-62-1P
816424-63-2P 816426-21-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thienopyridone derivs. as p38α kinase inhibitors)

RN 816423-93-5 ZCAPLUS

CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816423-94-6 ZCAPLUS

CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-3-[(3-methylphenyl)amino]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816423-95-7 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(3-chlorophenyl)amino]-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816423-96-8 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-(4-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816423-97-9 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-(4-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816423-98-0 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-(4-methylphenyl)-3-[(3-methylphenyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816423-99-1 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-7-(4-fluorophenyl)-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-00-7 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-7-(4-fluorophenyl)-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-01-8 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(2-chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-02-9 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(2-chlorophenyl)-3-[(2,4-difluorophenyl)amino]-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-03-0 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2-chlorophenyl)amino]-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-04-1 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2-chlorophenyl)amino]-2-[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-05-2 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl-3-(phenylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-06-3 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl-3-(phenylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-07-4 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-08-5 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl-3-(phenylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-09-6 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl-3-(phenylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-10-9 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(4-chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-11-0 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-2-[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-(3-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-12-1 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-(3-methylphenyl)-3-[(3-methylphenyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-13-2 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-(3-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-14-3 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(3-chloro-4-fluorophenyl)amino]-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-15-4 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(3-chloro-4-fluorophenyl)amino]-2-[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-16-5 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-17-6 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-2-[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-18-7 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-19-8 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(3R)-3-hydroxy-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-20-1 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-2-[[(3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-21-2 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-2-[[(3R)-3-hydroxy-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-22-3 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(3S,4S)-3,4-dihydroxy-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-23-4 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[(3-hydroxy-1-azetidinyl)carbonyl]-7-phenyl- (CA INDEX NAME)



RN 816424-24-5 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(2S)-2-(1-hydroxy-1-methylethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-25-6 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(2R)-2-(1-hydroxy-1-methylethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-26-7 ZCAPLUS
CN Benzonitrile, 2-[[6,7-dihydro-2-[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-6-oxo-7-phenylthieno[2,3-b]pyridin-3-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-27-8 ZCAPLUS
CN Benzonitrile, 2-[[6,7-dihydro-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-6-oxo-7-phenylthieno[2,3-b]pyridin-3-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-28-9 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(cyclopropylmethyl)-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-3-(phenylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-29-0 ZCAPLUS
CN Benzonitrile, 3-[[6,7-dihydro-2-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-6-oxo-7-phenylthieno[2,3-b]pyridin-3-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-31-4 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(3R)-3-amino-1-pyrrolidinyl]carbonyl]-3-[(2,4-difluorophenyl)amino]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-32-5 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(2S)-2-(aminomethyl)-1-pyrrolidinyl]carbonyl]-3-[(2,4-difluorophenyl)amino]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-33-6 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(2R)-2-(aminomethyl)-1-

pyrrolidinyl]carbonyl]-3-[(2,4-difluorophenyl)amino]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-34-7 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(3R)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-35-8 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[(4-hydroxy-1-piperidinyl)carbonyl]-7-phenyl- (CA INDEX NAME)



RN 816424-36-9 ZCAPLUS

CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[(3-hydroxy-1-piperidinyl)carbonyl]-7-phenyl- (CA INDEX NAME)



RN 816424-37-0 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(3R)-3-amino-1-pyrrolidinyl]carbonyl]-3-[(4-fluoro-3-methylphenyl)amino]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-38-1 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(2S)-2-(aminomethyl)-1-pyrrolidinyl]carbonyl]-3-[(4-fluoro-3-methylphenyl)amino]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-39-2 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(3R)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-3-[(4-fluoro-3-methylphenyl)amino]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-40-5 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(3R,4R)-3,4-dihydroxy-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-41-6 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(3R,4S)-3,4-dihydroxy-1-pyrrolidinyl]carbonyl]-7-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 816424-42-7 ZCAPLUS
CN Benzonitrile, 2-[[6,7-dihydro-2-[[(3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]-6-oxo-7-phenylthieno[2,3-b]pyridin-3-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-43-8 ZCAPLUS
CN Benzonitrile, 2-[[6,7-dihydro-2-[[(3R)-3-hydroxy-1-pyrrolidinyl]carbonyl]-6-oxo-7-phenylthieno[2,3-b]pyridin-3-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-44-9 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[(3-amino-1-pyrrolidinyl)carbonyl]-3-[(2,4-difluorophenyl)amino]-7-phenyl- (CA INDEX NAME)



RN 816424-45-0 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(3S)-3-amino-1-pyrrolidinyl]carbonyl]-3-[(2,4-difluorophenyl)amino]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-46-1 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(3S)-3-amino-1-pyrrolidinyl]carbonyl]-3-[(4-fluoro-3-methylphenyl)amino]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-47-2 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-7-(4-fluorophenyl)-2-[[(3R)-3-hydroxy-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-48-3 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-7-(4-fluorophenyl)-2-[[(3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-49-4 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-7-(4-fluorophenyl)-2-[[(3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-50-7 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(2-chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-2-[[(3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-51-8 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(2-chlorophenyl)-2-[[(3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]-3-[(3-methylphenyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-52-9 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(2-chlorophenyl)-3-[(2,4-difluorophenyl)amino]-2-[[(3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-53-0 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]-7-(4-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-54-1 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-2-[[(3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]-7-(4-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-55-2 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(3R)-3-hydroxy-1-pyrrolidinyl]carbonyl]-7-(4-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-56-3 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-2-[[(3R)-3-hydroxy-1-pyrrolidinyl]carbonyl]-7-(4-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-57-4 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-2-[(3-hydroxy-1-azetidinyl)carbonyl]-7-phenyl- (CA INDEX NAME)



RN 816424-58-5 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[(4-amino-1-piperidinyl)carbonyl]-3-[(2,4-difluorophenyl)amino]-7-phenyl- (CA INDEX NAME)



RN 816424-59-6 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[(3-amino-1-azetidinyl)carbonyl]-3-[(2,4-difluorophenyl)amino]-7-phenyl- (CA INDEX NAME)



RN 816424-60-9 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[4-(dimethylamino)-1-piperidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)



RN 816424-61-0 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[3-(dimethylamino)-1-azetidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)



RN 816424-62-1 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-3-[(4-fluoro-3-methylphenyl)amino]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-63-2 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(2-chlorophenyl)-3-[(2,4-difluorophenyl)amino]-2-[[(3R)-3-hydroxy-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816426-21-8 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-[[(3S)-3-

(dimethylamino)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 639479-13-3P, Ethyl 3-anilino-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 639479-14-4P, Ethyl 3-[(2-chlorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 639479-21-3P, Ethyl 3-[(3-cyanophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 639479-22-4P, Ethyl 3-[(2-cyanophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 639479-24-6P, Ethyl 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 639479-26-8P 639479-59-7P, Ethyl 3-anilino-7-(cyclopropylmethyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 639480-45-8P, Ethyl 3-[(3-chloro-4-fluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 639480-49-2P, Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-(4-chlorophenyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 639480-50-5P, Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-(3-methylphenyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 639480-51-6P, Ethyl 3-[(3-methylphenyl)amino]-6-oxo-7-(3-methylphenyl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 639482-02-3P 639482-11-4P 639504-79-3P, Ethyl 3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 816424-65-4P 816424-66-5P 816424-67-6P 816424-68-7P 816424-69-8P 816424-70-1P 816424-79-0P 816424-80-3P 816424-81-4P 816424-82-5P 816424-83-6P 816424-84-7P 816424-85-8P 816424-86-9P 816424-90-5P 816424-91-6P 816424-93-8P, Sodium 3-[(2-chlorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 816424-94-9P 816424-95-0P 816424-96-1P 816424-97-2P, Pentafluorophenyl 3-[(2-cyanophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 816425-03-3P 816425-04-4P 816425-05-5P 816425-07-7P 816425-08-8P 816425-09-9P 816425-15-7P 816425-16-8P 816425-17-9P 816425-20-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thienopyridone derivs. as p38α kinase inhibitors)

RN 639479-13-3 ZCAPLUS

CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639479-14-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-chlorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-21-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-cyanophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-22-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyanophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-24-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-26-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-(phenylamino)-, ammonium salt (1:1) (CA INDEX NAME)



RN 639479-59-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639480-45-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-chloro-4-fluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639480-49-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-(4-chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639480-50-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-7-(3-methylphenyl)-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639480-51-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-7-(3-methylphenyl)-3-[(3-methylphenyl)amino]-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639482-02-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, 2,3,4,5,6-pentafluorophenyl ester (CA INDEX NAME)



RN 639482-11-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, 2,3,4,5,6-pentafluorophenyl ester (CA INDEX NAME)



RN 639504-79-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 816424-65-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, lithium salt (1:1) (CA INDEX NAME)



● Li

RN 816424-66-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, lithium salt (1:1) (CA INDEX NAME)



● Li

RN 816424-67-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-(4-chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 816424-68-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-7-(3-methylphenyl)-6-oxo-, sodium salt (1:1) (CA INDEX NAME)



RN 816424-69-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-7-(3-methylphenyl)-3-[(3-methylphenyl)amino]-6-oxo-, sodium salt (1:1) (CA INDEX NAME)



RN 816424-70-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-chloro-4-fluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, sodium salt (1:1) (CA INDEX NAME)



RN 816424-79-0 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-7-phenyl-2-[[(2R)-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-80-3 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(3-methylphenyl)amino]-7-phenyl-2-[[(2R)-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-81-4 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(3-chlorophenyl)amino]-7-phenyl-2-[[(2R)-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-82-5 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-7-(4-methylphenyl)-2-[[(2R)-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-83-6 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-7-(4-methylphenyl)-2-[[(2R)-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-84-7 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(4-methylphenyl)-3-[(3-methylphenyl)amino]-2-[[(2R)-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-85-8 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-7-(4-fluorophenyl)-2-[[(2R)-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-86-9 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-7-(4-fluorophenyl)-2-[[(2R)-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-90-5 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(2-chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-2-[[(2R)-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-91-6 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(2-chlorophenyl)-3-[(2,4-difluorophenyl)amino]-2-[[(2R)-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-93-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-chlorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, sodium salt (1:1) (CA INDEX NAME)



RN 816424-94-9 ZCAPLUS
CN Carbamic acid, [1-[[3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl]carbonyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 816424-95-0 ZCAPLUS
CN Carbamic acid, [(3S)-1-[[3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl]carbonyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-96-1 ZCAPLUS
CN Carbamic acid, [(3S)-1-[[3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl]carbonyl]-3-pyrrolidinyl]-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-97-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyanophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, 2,3,4,5,6-pentafluorophenyl ester (CA INDEX NAME)



RN 816425-03-3 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-7-(4-fluorophenyl)-2-[[(3R)-3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816425-04-4 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-7-(4-fluorophenyl)-2-[[(3S)-3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816425-05-5 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-7-(4-fluorophenyl)-2-[[(3S)-3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816425-07-7 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(2-chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-2-[[(3S)-3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816425-08-8 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(2-chlorophenyl)-3-[(3-methylphenyl)amino]-2-[[(3S)-3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816425-09-9 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(2-chlorophenyl)-3-[(2,4-difluorophenyl)amino]-2-[[(3S)-3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 816425-15-7 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-7-phenyl-2-[[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-azetidinyl]carbonyl]- (CA INDEX NAME)



RN 816425-16-8 ZCAPLUS
CN Carbamic acid, [1-[[3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 816425-17-9 ZCAPLUS
CN Carbamic acid, [1-[[3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl]carbonyl]-3-azetidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 816425-20-4 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-(2-chlorophenyl)-3-[(2,4-difluorophenyl)amino]-2-[[(3R)-3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2004:143162 ZCAPLUS Full-text
DOCUMENT NUMBER: 140:181432
TITLE: Preparation of bicyclic heteroaromatic compounds as p38 kinase inhibitors
INVENTOR(S): Brookings, Daniel Christopher; Davis, Jeremy Martin; Langham, Barry John
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014920	A1	20040219	WO 2003-GB3501	20030811

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2495518	A1	20040219	CA 2003-2495518		20030811
AU 2003252990	A1	20040225	AU 2003-252990		20030811
EP 1539769	A1	20050615	EP 2003-784288		20030811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005537300	T	20051208	JP 2004-527055		20030811
US 20060025428	A1	20060202	US 2005-524199		20050728
PRIORITY APPLN. INFO.:			GB 2002-18800	A	20020813
			WO 2003-GB3501	W	20030811

OTHER SOURCE(S): MARPAT 140:181432

GI



I



II

AB Title compds. I [A = N, (un)substituted CH, dashed line is a double bond; A = (un)substituted NH, CH2, dashed line is a single bond; X = O, S, (un)substituted NH, S(O), SO2; Y = N, (un)substituted CH; Alk = (un)substituted aliphatic, heteroaliph.; n = 0, 1; Ar = (un)substituted aromatic, heteroarom.; L = atom, alkylene, heteroalkylene; L1 = bond, linker atom, linker group; Cy = H, (un)substituted cycloaliph, polycycloaliph., heterocyclic, polyheterocyclic, aromatic, heteroarom.; R = H, CN, (un)substituted alkyl,CO2H, CONH2], especially 6-oxo-6,7-dihydrothieno[2,3-b]pyridine derivs., which are inhibitors of p38 kinase of use in the treatment and/or prevention of immune or inflammatory disorders (no data) were prepared Thus, II [R1 = NHCH2Ph, r2 = Ph] was prepared from 2-chloronicotinonitrile and HSCH2CO2Et via II [R1 = Br, R2 = H] by treatment with PhB(OH)2 and PhCH2NH2.

IT 660398-75-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bicyclic heteroarom. compds. as p38 kinase inhibitors)

RN 660398-75-4 ZCAPLUS

CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-(2-phenylethynyl)-, ethyl ester (CA INDEX NAME)



IT 660398-49-2P 660398-50-5P 660398-51-6P
660398-52-7P 660398-53-8P 660398-54-9P
660398-55-0P 660398-56-1P 660398-58-3P
660398-59-4P 660398-60-7P 660398-61-8P
660398-62-9P 660398-63-0P 660398-64-1P
660398-65-2P 660398-68-5P 660398-69-6P
660398-70-9P 660398-71-0P 660398-72-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic heteroarom. compds. as p38 kinase inhibitors)

RN 660398-49-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-[(phenylmethyl)amino]-, ethyl ester (CA INDEX NAME)



RN 660398-50-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[methyl(phenylmethyl)amino]-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 660398-51-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-[(1-phenylethyl)amino]-, ethyl ester (CA INDEX NAME)



RN 660398-52-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[[(2,6-difluorophenyl)methyl]amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 660398-53-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-(phenylmethyl)-, ethyl ester (CA INDEX NAME)



RN 660398-54-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-3-phenoxy-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 660398-55-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-(phenylthio)-, ethyl ester (CA INDEX NAME)



RN 660398-56-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-[(2-pyridinylmethyl)amino]-, ethyl ester (CA INDEX NAME)



RN 660398-58-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-6-oxo-7-phenyl-3-(phenylthio)- (CA INDEX NAME)



RN 660398-59-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-(benzoylamino)-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 660398-60-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-[(phenylsulfonyl)amino]-, ethyl ester (CA INDEX NAME)



RN 660398-61-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-[[(phenylamino)carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 660398-62-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-(2-phenylethyl)-, ethyl ester (CA INDEX NAME)



RN 660398-63-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-(hydroxyphenylmethyl)-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 660398-64-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[hydroxy(6-methyl-2-pyridinyl)methyl]-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 660398-65-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[hydroxy(3-methylphenyl)methyl]-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 660398-68-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-(cyclopropylmethyl)-6,7-dihydro-3-(hydroxyphenylmethyl)-6-oxo-, ethyl ester (CA INDEX NAME)



RN 660398-69-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-[(phenylamino)sulfonyl]-, ethyl ester (CA INDEX NAME)



RN 660398-70-9 ZCAPLUS

CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[(3-methylphenyl)thio]-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 660398-71-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[2-(4-methylphenyl)hydrazinyl]-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 660398-72-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-chlorophenyl)hydroxymethyl]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 2004:2888 ZCAPLUS Full-text
DOCUMENT NUMBER: 140:59658
TITLE: Preparation of arylamine substituted bicyclic hetero-aromatic compounds as p38 kinase inhibitors
INVENTOR(S): Brookings, Daniel Christopher; Davis, Jeremy Martin; Langham, Barry John
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 174 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004000846	A1	20031231	WO 2003-GB2667	20030620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487718	A1	20031231	CA 2003-2487718	20030620
AU 2003253087	A1	20040106	AU 2003-253087	20030620
BR 2003011842	A	20050315	BR 2003-11842	20030620
EP 1551848	A1	20050713	EP 2003-760802	20030620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1671715	A	20050921	CN 2003-818371	20030620
JP 2005530838	T	20051013	JP 2004-515043	20030620
NZ 537740	A	20060331	NZ 2003-537740	20030620
MX 2004PA12746	A	20050323	MX 2004-PA12746	20041215
NO 2005000306	A	20050316	NO 2005-306	20050119
ZA 2005000524	A	20060830	ZA 2005-524	20050119
US 20060004025	A1	20060105	US 2005-518725	20050526
PRIORITY APPLN. INFO.:			GB 2002-14268 A	20020620
			WO 2003-GB2667 W	20030620

OTHER SOURCE(S): MARPAT 140:59658
GI



I

AB Bicyclic heteroarom. derivs. I; where the dashed line joining A and C(Ra) is present and represents a bond and A is a -N= atom or a -C(Rb)= group, or the dashed line is absent and A is a -N(Rb)-, or -C(Rb)(Rc)- group; X is an -O-, -S- or substituted nitrogen atom or a -S(O)-, -S(O2)- or -NH- group; Y is a nitrogen or substituted carbon atom or a -CH = group; n is zero or the integer 1; Alkl is an optionally substituted aliphatic or hetero-aliphatic chain Ll is a covalent bond or a linker atom or group; Cyl is a hydrogen atom or an optionally substituted cyclo-aliphatic, poly-cyclo-aliphatic, hetero-cyclo-aliphatic, poly-hetero-cyclo-aliphatic, aromatic or hetero-aromatic group; Ar is an optionally substituted aromatic or heteroarom. group; and the remaining substituents are defined in the specification. The compds. are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders. Thus, 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-N-pyrrolidin-3-yl-6,7- dihydrothieno[2,3-b]pyridine-2-carboxamide was prepared as as p38 kinase inhibitor. In the p38 inhibitor assays described above compds. of the invention have IC50 values of

around 1 μM and below. The compds. of the invention are clearly potent inhibitors of p38 kinase, especially p38α kinase.

IT 639479-13-3P 639479-14-4P 639479-15-5P
639479-21-3P 639479-22-4P 639479-24-6P
639479-26-8P 639479-52-0P 639479-54-2P
639479-74-6P 639479-78-0P 639479-80-4P
639479-82-6P 639479-84-8P 639479-93-9P
639479-94-0P 639479-96-2P 639479-98-4P
639479-99-5P 639480-02-7P 639480-05-0P
639480-06-1P 639480-10-7P 639480-12-9P
639480-41-4P 639480-42-5P 639480-43-6P
639480-45-8P 639480-46-9P 639480-47-0P
639480-48-1P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of arylamine substituted bicyclic hetero-aromatic compds. as p38 kinase inhibitors)

RN 639479-13-3 ZCAPLUS

CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639479-14-4 ZCAPLUS

CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-chlorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-15-5 ZCAPLUS

CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-chlorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-21-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-cyanophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-22-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyanophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-24-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-26-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-(phenylamino)-, ammonium salt (1:1) (CA INDEX NAME)



RN 639479-52-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-7-(1H-indol-5-yl)-6-oxo-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639479-54-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyanophenyl)amino]-6,7-dihydro-7-(1H-indol-5-yl)-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639479-74-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyano-3-methylphenyl)amino]-7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639479-78-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-bromophenyl)amino]-7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639479-80-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-3-(phenylamino)-7-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 639479-82-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyanophenyl)amino]-6,7-dihydro-6-oxo-7-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 639479-84-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 639479-93-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyanophenyl)amino]-6,7-dihydro-7-[4-(methylthio)phenyl]-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639479-94-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyanophenyl)amino]-6,7-dihydro-7-[4-(methylsulfinyl)phenyl]-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639479-96-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-7-[4-(methylthio)phenyl]-6-oxo-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639479-98-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[(3-methylphenyl)amino]-7-[4-(methylthio)phenyl]-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639479-99-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[(3-methylphenyl)amino]-7-[4-(methylsulfonyl)phenyl]-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639480-02-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-7-[4-[2-(2-methyl-1H-imidazol-1-yl)ethoxy]phenyl]-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639480-05-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-(4-ethenylphenyl)-6,7-dihydro-6-oxo-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639480-06-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(4-ethenylphenyl)-6,7-dihydro-6-oxo-3-(phenylamino)- (CA INDEX NAME)



RN 639480-10-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-7-(2-nitrophenyl)-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639480-12-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-4-methyl-6-oxo-7-phenyl-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639480-41-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyano-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639480-42-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyano-5-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639480-43-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluorophenyl)amino]-6,7-

dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639480-45-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-chloro-4-fluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639480-46-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyanophenyl)amino]-7-(4-fluorophenyl)-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639480-47-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyano-3-methylphenyl)amino]-7-(4-fluorophenyl)-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639480-48-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-7-(4-fluorophenyl)-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



IT 639479-16-6P 639479-17-7P 639479-18-8P
639479-19-9P 639479-20-2P 639479-23-5P
639479-25-7P 639479-29-1P 639479-30-4P
639479-37-1P 639479-39-3P 639479-40-6P
639479-42-8P 639479-44-0P 639479-46-2P
639479-49-5P 639479-50-8P 639479-51-9P
639479-53-1P 639479-55-3P 639479-56-4P
639479-57-5P 639479-59-7P 639479-60-0P
639479-61-1P 639479-62-2P 639479-63-3P
639479-69-9P 639479-70-2P 639479-71-3P
639479-72-4P 639479-73-5P 639479-75-7P
639479-76-8P 639479-79-1P 639479-81-5P
639479-83-7P 639479-85-9P 639479-86-0P
639479-87-1P 639479-88-2P 639479-90-6P
639479-92-8P 639479-95-1P 639479-97-3P
639480-00-5P 639480-01-6P 639480-03-8P
639480-04-9P 639480-07-2P 639480-08-3P
639480-11-8P 639480-13-0P 639480-15-2P
639480-16-3P 639480-17-4P 639480-19-6P
639480-20-9P 639480-21-0P 639480-22-1P
639480-23-2P 639480-24-3P 639480-25-4P
639480-26-5P 639480-27-6P 639480-28-7P
639480-29-8P 639480-30-1P 639480-31-2P
639480-32-3P 639480-33-4P 639480-34-5P
639480-35-6P 639480-36-7P 639480-37-8P
639480-38-9P 639480-39-0P 639480-40-3P
639480-44-7P 639480-49-2P 639480-50-5P
639480-51-6P 639480-77-6P 639480-78-7P
639480-79-8P 639480-80-1P 639480-81-2P
639480-82-3P 639480-83-4P 639480-84-5P
639480-85-6P 639480-86-7P 639480-87-8P
639480-88-9P 639480-89-0P 639480-90-3P
639480-91-4P 639480-92-5P 639480-93-6P
639480-94-7P 639480-95-8P 639480-96-9P
639480-97-0P 639480-98-1P 639480-99-2P
639481-00-8P 639481-01-9P 639481-02-0P
639481-03-1P 639481-04-2P 639481-05-3P
639481-09-7P 639481-10-0P 639481-12-2P
639481-13-3P 639481-15-5P 639481-16-6P

639481-18-8P 639481-19-9P 639481-20-2P
639481-21-3P 639481-22-4P 639481-23-5P
639481-24-6P 639481-25-7P 639481-26-8P
639481-27-9P 639504-80-6P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylamine substituted bicyclic hetero-aromatic compds. as p38
kinase inhibitors)

RN 639479-16-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-chlorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-17-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-(methylphenylamino)-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-18-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[(2-methoxyphenyl)amino]-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-19-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-[[3-(trifluoromethoxy)phenyl]amino]-, ethyl ester (CA INDEX NAME)



RN 639479-20-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-cyanophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-23-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-fluoro-4-methoxyphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-25-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-3-[(3-methylphenyl)amino]-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-29-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639479-30-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-6-oxo-7-phenyl-3-(phenylamino)-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 639479-37-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(2-chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639479-39-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(2-chlorophenyl)-6,7-dihydro-6-oxo-3-(phenylamino)- (CA INDEX NAME)



RN 639479-40-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-7-(4-methylphenyl)-6-oxo- (CA INDEX NAME)



RN 639479-42-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-7-(4-methylphenyl)-3-[(3-methylphenyl)amino]-6-oxo- (CA INDEX NAME)



RN 639479-44-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-cyclopropyl-3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639479-46-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-cyclopropyl-6,7-dihydro-3-[(3-methylphenyl)amino]-6-oxo- (CA INDEX NAME)



RN 639479-49-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-7-(2-methylphenyl)-3-[(3-

methylphenyl)amino]-6-oxo- (CA INDEX NAME)



RN 639479-50-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-7-(2-methylphenyl)-6-oxo- (CA INDEX NAME)



RN 639479-51-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-7-(2-methylphenyl)-6-oxo- (CA INDEX NAME)



RN 639479-53-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-7-(1H-indol-5-yl)-6-oxo-3-(phenylamino)- (CA INDEX NAME)



RN 639479-55-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2-cyanophenyl)amino]-6,7-dihydro-7-(1H-indol-5-yl)-6-oxo- (CA INDEX NAME)



RN 639479-56-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyanophenyl)amino]-6,7-dihydro-7-[1-(methylsulfonyl)-1H-indol-5-yl]-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639479-57-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-cyanophenyl)amino]-6,7-dihydro-7-(1-methyl-1H-indol-5-yl)-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639479-59-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639479-60-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-3-(phenylamino)- (CA INDEX NAME)



RN 639479-61-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(cyclopropylmethyl)-6,7-dihydro-N-methoxy-N-methyl-6-oxo-3-(phenylamino)- (CA INDEX NAME)



RN 639479-62-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-(cyclopropylmethyl)-3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639479-63-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(cyclopropylmethyl)-3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639479-69-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(cyclopropylmethyl)-6,7-dihydro-3-[(3-methylphenyl)amino]-6-oxo- (CA INDEX NAME)



RN 639479-70-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(cyclopropylmethyl)-3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639479-71-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethyl)-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639479-72-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(cyclopropylmethyl)-3-[(2,4-dimethylphenyl)amino]-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639479-73-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(cyclopropylmethyl)-3-[(3,4-dimethylphenyl)amino]-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639479-75-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2-cyano-3-methylphenyl)amino]-7-(cyclopropylmethyl)-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639479-76-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-3-(phenylamino)-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 639479-79-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(3-bromophenyl)amino]-7-(cyclopropylmethyl)-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639479-81-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-6-oxo-3-(phenylamino)-7-(3-thienyl)- (CA INDEX NAME)



RN 639479-83-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2-cyanophenyl)amino]-6,7-dihydro-6-oxo-7-(3-thienyl)- (CA INDEX NAME)



RN 639479-85-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-(3-thienyl)- (CA INDEX NAME)



RN 639479-86-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-(3-thienyl)- (CA INDEX NAME)



RN 639479-87-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-(3-pyridinylamino)-, ethyl ester (CA INDEX NAME)



RN 639479-88-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2-chloro-3-pyridinyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639479-90-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-3-[(6-methyl-2-pyridinyl)amino]-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639479-92-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(6-chloro-2-pyridinyl)amino]-6,7-

dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639479-95-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2-cyanophenyl)amino]-6,7-dihydro-7-[4-(methylsulfinyl)phenyl]-6-oxo- (CA INDEX NAME)



RN 639479-97-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-7-[4-(methylsulfinyl)phenyl]-6-oxo-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639480-00-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-3-[(3-methylphenyl)amino]-7-[4-(methylsulfonyl)phenyl]-6-oxo- (CA INDEX NAME)



RN 639480-01-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-3-(phenylamino)-7-[4-(1-pyrrolidinylmethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 639480-03-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-7-[4-[2-(2-methyl-1H-imidazol-1-yl)ethoxy]phenyl]-6-oxo- (CA INDEX NAME)



RN 639480-04-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-7-(4-ethenylphenyl)-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639480-07-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-[4-(1,2-dihydroxyethyl)phenyl]-6,7-dihydro-6-oxo-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639480-08-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-[4-(1,2-dihydroxyethyl)phenyl]-6,7-dihydro-6-oxo-3-(phenylamino)- (CA INDEX NAME)



RN 639480-11-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-7-(2-nitrophenyl)-6-oxo- (CA INDEX NAME)



RN 639480-13-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-4-methyl-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-15-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-7-[2-(2-methoxyethoxy)ethyl]-6-oxo-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639480-16-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-[(tetrahydro-2H-pyran-2-yl)methyl]-, ethyl ester (CA INDEX NAME)



RN 639480-17-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-3-(phenylamino)-7-(phenylmethyl)-, ethyl ester (CA INDEX NAME)



RN 639480-19-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-6-oxo-3-(phenylamino)-7-(phenylmethyl)- (CA INDEX NAME)



RN 639480-20-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-7-phenyl-3-(phenylamino)-, hydrazide (CA INDEX NAME)



RN 639480-21-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-[4-(dimethylamino)phenyl]-6,7-dihydro-6-oxo-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639480-22-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-[4-(dimethylamino)phenyl]-6,7-dihydro-N-methoxy-N-methyl-6-oxo-3-(phenylamino)- (CA INDEX NAME)



RN 639480-23-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-[4-(dimethylamino)phenyl]-6,7-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-6-oxo-3-(phenylamino)- (CA INDEX NAME)



RN 639480-24-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-[4-(dimethylamino)phenyl]-6,7-dihydro-6-oxo-3-(phenylamino)-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 639480-25-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-N,N-dimethyl-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-26-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, N,N-diethyl-6,7-dihydro-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-27-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-N-methoxy-N-methyl-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-28-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-N-[3-(4-methyl-1-piperazinyl)propyl]-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-29-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-30-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, N-[2-(diethylamino)ethyl]-6,7-dihydro-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-31-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, N-[2-(diethylamino)ethyl]-6,7-dihydro-N-methyl-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-32-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-N-methyl-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-33-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, N-ethyl-6,7-dihydro-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-34-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-N-[2-(4-morpholinyl)ethyl]-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-35-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, N-[2-(dimethylamino)ethyl]-6,7-dihydro-N-methyl-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-36-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-N-[3-(4-morpholinyl)propyl]-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-37-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-N-methoxy-N-methyl-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-38-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 639480-39-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-N-(2-hydroxy-1,1-dimethylethyl)-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639480-40-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-chloro-2-cyanophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639480-44-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-chloro-4-cyanophenyl)amino]-

6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639480-49-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-(4-chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639480-50-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-7-(3-methylphenyl)-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639480-51-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-7-(3-methylphenyl)-3-[(3-methylphenyl)amino]-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639480-77-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(4-fluorophenyl)-6,7-dihydro-3-[(3-methylphenyl)amino]-6-oxo- (CA INDEX NAME)



RN 639480-78-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-79-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-6-oxo-7-phenyl-3-[[3-(trifluoromethyl)phenyl]amino]- (CA INDEX NAME)



RN 639480-80-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(3,5-dichlorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-81-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(3-bromophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-82-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-6-oxo-7-phenyl-3-[[2-(trifluoromethoxy)phenyl]amino]- (CA INDEX NAME)



RN 639480-83-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[[2-(difluoromethoxy)phenyl]amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-84-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,6-dichlorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-85-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-3-[(3-methylphenyl)amino]-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-86-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(3-bromo-4-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-87-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-3-[[3-(methylthio)phenyl]amino]-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-88-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-6-oxo-7-phenyl-3-[[3-(trifluoromethoxy)phenyl]amino]- (CA INDEX NAME)



RN 639480-89-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-90-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-6-oxo-7-phenyl-3-[[3-[(trifluoromethyl)thio]phenyl]amino]- (CA INDEX NAME)



RN 639480-91-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(3-ethylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-92-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(2-chlorophenyl)-6,7-dihydro-3-[(3-methylphenyl)amino]-6-oxo- (CA INDEX NAME)



RN 639480-93-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2-cyano-3-methylphenyl)amino]-7-(4-fluorophenyl)-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639480-94-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(4-fluoro-3-methylphenyl)amino]-7-(4-fluorophenyl)-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639480-95-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2-cyanophenyl)amino]-7-(4-fluorophenyl)-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639480-96-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-3-[(2-hydroxyphenyl)amino]-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-97-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-3-[(3-hydroxyphenyl)amino]-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-98-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2-cyanophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639480-99-2 ZCAPLUS

CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2-chlorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-00-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(3-cyanophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-01-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2-cyano-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-02-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2-cyano-5-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-03-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(3-chloro-4-fluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-04-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(4-fluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-05-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(3-chlorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-09-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-N-(2-hydroxy-2-methylpropyl)-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-10-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-

dihydro-6-oxo-7-phenyl-, 2-(methoxycarbonyl)hydrazide (CA INDEX NAME)



RN 639481-12-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-7-[4-(1-hydroxy-1-methylethyl)phenyl]-6-oxo-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639481-13-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-7-[4-[(methylsulfonyl)amino]phenyl]-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639481-15-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-N-hydroxy-N-methyl-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-16-6 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-acetyl-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639481-18-8 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-phenyl-3-(phenylamino)-2-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)



RN 639481-19-9 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-phenyl-3-(phenylamino)-2-(1-piperidinylcarbonyl)- (CA INDEX NAME)



RN 639481-20-2 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[(4-ethyl-1-piperazinyl)carbonyl]-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639481-21-3 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-[4-(dimethylamino)phenyl]-3-(phenylamino)-2-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)



RN 639481-22-4 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-2-(4-morpholinylcarbonyl)-7-phenyl- (CA INDEX NAME)



RN 639481-23-5 ZCAPLUS
CN Benzonitrile, 3-[[6,7-dihydro-6-oxo-7-phenyl-2-(1-pyrrolidinylcarbonyl)thieno[2,3-b]pyridin-3-yl]amino]- (CA INDEX NAME)



RN 639481-24-6 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(3-chlorophenyl)amino]-7-phenyl-2-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)



RN 639481-25-7 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(2,4-difluorophenyl)amino]-7-phenyl-2-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)



RN 639481-26-8 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluorophenyl)amino]-7-phenyl-2-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)



RN 639481-27-9 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-N-3-pyrrolidinyl- (CA INDEX NAME)



RN 639504-80-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-6-oxo-3-(phenylamino)-7-(3-pyridinyl)- (CA INDEX NAME)



IT 639481-52-0P 639481-55-3P 639481-58-6P
639481-64-4P 639481-65-5P 639481-66-6P
639481-73-5P 639481-87-1P 639481-90-6P
639481-91-7P 639481-99-5P 639482-00-1P
639482-02-3P 639482-06-7P 639482-07-8P
639482-09-0P 639482-10-3P 639482-11-4P
639482-17-0P 639504-79-3P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylamine substituted bicyclic hetero-aromatic compds. as p38
kinase inhibitors)
RN 639481-52-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-(cyclopropylmethyl)-6,7-dihydro-6-oxo-3-(phenylamino)-, ammonium salt (1:1) (CA INDEX NAME)



RN 639481-55-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-3-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 639481-58-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639481-64-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-7-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639481-65-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-7-(4-hydroxyphenyl)-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639481-66-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-[4-(2-bromoethoxy)phenyl]-3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639481-73-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-7-(2-nitrophenyl)-6-oxo-, sodium salt (1:1) (CA INDEX NAME)



RN 639481-87-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 6,7-dihydro-6-oxo-3-(phenylamino)-7-(phenylmethyl)-, ammonium salt (1:1) (CA INDEX NAME)



RN 639481-90-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-[4-(dimethylamino)phenyl]-6,7-dihydro-6-oxo-3-(phenylamino)-, ammonium salt (1:1) (CA INDEX NAME)



RN 639481-91-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ammonium salt (1:1) (CA INDEX NAME)



RN 639481-99-5 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-chloro-4-

fluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ammonium salt (1:1) (CA INDEX NAME)



RN 639482-00-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(3-chlorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ammonium salt (1:1) (CA INDEX NAME)



RN 639482-02-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, 2,3,4,5,6-pentafluorophenyl ester (CA INDEX NAME)



RN 639482-06-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(2,4-difluorophenyl)amino]-7-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639482-07-8 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-(4-aminophenyl)-3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639482-09-0 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-[4-[bis(methylsulfonyl)amino]phenyl]-3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



RN 639482-10-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ammonium salt (1:1) (CA INDEX NAME)



RN 639482-11-4 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, 2,3,4,5,6-pentafluorophenyl ester (CA INDEX NAME)



RN 639482-17-0 ZCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl]carbonyl]amino]-, phenylmethyl ester (CA INDEX NAME)



RN 639504-79-3 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



IT 639482-18-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of arylamine substituted bicyclic hetero-aromatic compds. as p38
kinase inhibitors)
RN 639482-18-1 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 7-(cyclopropylmethyl)-3-[(2,4-difluorophenyl)amino]-6,7-dihydro-6-oxo- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1154722 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:93797
TITLE: Process for preparing 3-aminothienopyridone derivatives and their applications to the synthesis of p38 MAP kinase inhibitors
INVENTOR(S): Evans, Graham Robert; Smith, Ian Harold; Tremayne, Neil; Jones, Leighton; Langston, Marianne
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113349	A1	20041229	WO 2004-GB2680	20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004249507	A1	20041229	AU 2004-249507		20040618
CA 2528927	A1	20041229	CA 2004-2528927		20040618
EP 1638980	A1	20060329	EP 2004-743031		20040618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
JP 2007516163	T	20070621	JP 2006-516465		20040618
US 20070191608	A1	20070816	US 2006-561051		20060608
PRIORITY APPLN. INFO.:			GB 2003-14493	A	20030620
			GB 2003-29471	A	20031219
			WO 2004-GB2680	W	20040618

OTHER SOURCE(S): MARPAT 142:93797

GI



I II III IV V

AB This invention provides a class of 3-amino-7H-thieno[2,3-b]pyridin-6-one derivs. I [wherein R = cyano, NO2, CO2Alk2, C(O)alkyl, CONHHet2; Alk2 = (un)substituted alkyl or aryl; Het2 = (un)substituted 4/5/6-membered heterocycloalkyl; R1 = (un)substituted (hetero)aryl or (hetero)cycloalkyl; R2, R3 = H or a hydrogen atom precursor, or salts, solvates, hydrates, protected derivs. and N-oxides thereof], a process for their prepns., and the use thereof as intermediates in the manufacture of certain p38 MAP kinase inhibitors. For example, 2-cyano-N-phenylthioacetamide was treated with N,N-dimethyluracil to give crude thiolate II containing about 20% ethanol, which was directly refluxed with chloroacetonitrile in acetonitrile for 2 h to afford amine III. This compound underwent diazotization and subsequent halide displacement with tert-butylnitrite and CuBr2, leading to bromide IV. Pd-catalyzed N-alkylation of III with bromobenzene or amination of IV with aniline yielded V. Conversion of this product to the corresponding carboxamide was realized by the hydrolysis of the cyano group in the presence of NaOH-H2O-Ethanol system.

IT 817177-54-1P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for preparing 3-aminothienopyridone derivs. and their applications to the synthesis of p38 MAP kinase inhibitors)

RN 817177-54-1 ZCAPLUS

CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-7-

phenyl-2-[[(3R)-3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-pyrrolidinyl]carbonyl]-
(CA INDEX NAME)

Absolute stereochemistry.



IT 639479-29-1P, 6-Oxo-7-phenyl-3-phenylamino-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 639479-37-1P, 7-(2-Chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 639479-46-2P, 7-Cyclopropyl-3-[(3-methylphenyl)amino]-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 639480-85-6P, 6-Oxo-7-phenyl-3-(m-tolylamino)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 639481-18-8P, 7-Phenyl-3-phenylamino-2-[(pyrrolidin-1-yl)carbonyl]-7H-thieno[2,3-b]pyridin-6-one 639481-20-2P, 2-([4-Ethylpiperazin-1-yl]carbonyl)-7-phenyl-3-phenylamino-7H-thieno[2,3-b]pyridin-6-one 816424-17-6P, (S)-3-(4-Fluoro-3-methylphenylamino)-2-[(2-hydroxymethylpyrrolidin-1-yl)carbonyl]-7-phenyl-7H-thieno[2,3-b]pyridin-6-one 816424-21-2P, (R)-3-(4-Fluoro-3-methylphenylamino)-2-[(3-hydroxypyrrolidin-1-yl)carbonyl]-7-phenyl-7H-thieno[2,3-b]pyridin-6-one
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparing 3-aminothienopyridone derivs. and their applications to the synthesis of p38 MAP kinase inhibitors)

RN 639479-29-1 ZCAPLUS

CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-6-oxo-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 639479-37-1 ZCAPLUS

CN Thieno[2,3-b]pyridine-2-carboxamide, 7-(2-chlorophenyl)-3-[(4-fluoro-3-methylphenyl)amino]-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639479-46-2 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 7-cyclopropyl-6,7-dihydro-3-[(3-methylphenyl)amino]-6-oxo- (CA INDEX NAME)



RN 639480-85-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-2-carboxamide, 6,7-dihydro-3-[(3-methylphenyl)amino]-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-18-8 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 7-phenyl-3-(phenylamino)-2-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)



RN 639481-20-2 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-[(4-ethyl-1-piperazinyl)carbonyl]-7-phenyl-3-(phenylamino)- (CA INDEX NAME)



RN 816424-17-6 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-2-[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 816424-21-2 ZCAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-[(4-fluoro-3-methylphenyl)amino]-2-[[(3R)-3-hydroxy-1-pyrrolidinyl]carbonyl]-7-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:531099 ZCAPLUS Full-text
DOCUMENT NUMBER: 117:131099
ORIGINAL REFERENCE NO.: 117:22763a,22766a

TITLE: One-pot synthesis of polyfunctionally substituted thiophenes: thieno[2,3-b]pyridine and thieno[3,4-d]pyridazine derivatives

AUTHOR(S): Mohareb, Rafat Milad
CORPORATE SOURCE: Fac. Sci., Cairo Univ., Giza, Egypt

SOURCE: Gazzetta Chimica Italiana (1992), 122(4), 147-50
CODEN: GCITA9; ISSN: 0016-5603
DOCUMENT TYPE: Journal
LANGUAGE: English

GI



I II III

AB The enaminonitriles EtO2CCH2C(NH2):C(CN)CO2Et), NCCH2C(NH2):C(CN)2, and MeC(:NH)CH2CN treated with Ph isothiocyanate followed by cyclization with PHCH2COBr gave the thiophene I, the thieno[2,3-b]pyridine II and the thiophene III, resp. The reactivity of the reaction products toward different reagents to form heterocyclic and fused heterocyclic ring systems was confirmed.

IT 143208-40-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cyclization by formaldehyde)
RN 143208-40-6 ZCAPLUS
CN Thieno[2,3-b]pyridine-5-carbonitrile, 4-amino-2-benzoyl-6,7-dihydro-6-oxo-7-phenyl-3-[(phenylmethylene)amino]- (CA INDEX NAME)



IT 143208-33-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cyclocondensation with formaldehyde)
RN 143208-33-7 ZCAPLUS
CN Thieno[2,3-b]pyridine-5-carbonitrile, 4-amino-2-benzoyl-6,7-dihydro-3-[[(2-hydroxyphenyl)methylene]amino]-6-oxo-7-phenyl- (CA INDEX NAME)



IT 143208-41-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 143208-41-7 ZCAPLUS
CN Thieno[3',2':5,6]pyrido[4,3-d]pyrimidine-4,5(1H,6H)-dione,
8-benzoyl-6-phenyl-9-[(phenylmethylene)amino]- (9CI) (CA INDEX NAME)



L18 ANSWER 8 OF 10 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	5464082
Beilstein Pref. RN (BPR):	143208-33-7
CAS Reg. No. (RN):	143208-33-7
Chemical Name (CN):	4-amino-2-benzoyl-5-cyano-3-(o-hydroxy)benzalimino-6-oxo-7-phenylthieno<2,3-b>pyridine
Autonom Name (AUN):	4-amino-2-benzoyl-3-<(2-hydroxy-benzylidene)-amino>-6-oxo-7-phenyl-6,7-dihydro-thieno<2,3-b>pyridine-5-carbonitrile
Molec. Formula (MF):	C28 H18 N4 O3 S
Molecular Weight (MW):	490.54
Lawson Number (LN):	31717, 14131, 8629
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	4809936
Tautomer ID (TAUTID):	5214892
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1993/05/04
Update Date (DUPD):	1994/02/18



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	3
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
NMR	Nuclear Magnetic Resonance	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

All References:
ALLREF

1. Mohareb, Rafat Milad, Gazz.Chim.Ital., CODEN: GCITA9, 122(4), <1992>, 147-150; BABS-5657665

L18 ANSWER 9 OF 10 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	5463664
Beilstein Pref. RN (BPR):	143208-41-7
CAS Reg. No. (RN):	143208-41-7
Chemical Name (CN):	3-benzalimino-2-benzoyl-7-hydroxy-8-oxo-9-phenylthieno<2,3:6',5'>pyrido<4,3-d>pyrimidine
Autonom Name (AUN):	2-benzoyl-1-(benzylidene-amino)-6-hydroxy-4-phenyl-4H-3-thia-4,7,9-triaza-cyclopenta<a>naphthalen-5-one
Molec. Formula (MF):	C29 H18 N4 O3 S
Molecular Weight (MW):	502.55
Lawson Number (LN):	32493, 14131, 7132
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	4807588
Tautomer ID (TAUTID):	5203149
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1993/05/04
Update Date (DUPD):	1994/02/18



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	3
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1

ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
NMR	Nuclear Magnetic Resonance	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

All References:
ALLREF

1. Mohareb, Rafat Milad, Gazz.Chim.Ital., CODEN: GCITA9, 122(4), <1992>, 147-150; BABS-5657665

L18 ANSWER 10 OF 10 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	5462572
Beilstein Pref. RN (BPR):	143208-40-6
CAS Reg. No. (RN):	143208-40-6
Chemical Name (CN):	4-amino-3-benzalimino-2-benzoyl-5-cyano-6-oxo-7-phenylthieno<2,3-b>pyridine
Autonom Name (AUN):	4-amino-2-benzoyl-3-(benzylidene-amino)-6-oxo-7-phenyl-6,7-dihydro-thieno<2,3-b>pyridine-5-carbonitrile
Molec. Formula (MF):	C28 H18 N4 O2 S
Molecular Weight (MW):	474.54
Lawson Number (LN):	31717, 14131, 7132
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	4807179
Tautomer ID (TAUTID):	5201459
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1993/05/04
Update Date (DUPD):	1994/02/18



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	3
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
NMR	Nuclear Magnetic Resonance	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	1

All References:
ALLREF

1. Mohareb, Rafat Milad, Gazz.Chim.Ital., CODEN: GCITA9, 122(4), <1992>, 147-150; BABS-5657665

```
=> d his full

     (FILE 'HOME' ENTERED AT 08:37:37 ON 25 JUN 2008)

     FILE 'REGISTRY' ENTERED AT 08:37:50 ON 25 JUN 2008
L1                STRUCTURE UPLOADED
L2             21 SEA SSS SAM L1
                  D SCA
                  D STAT QUE L2
L3            375 SEA SSS FUL L1
                  SAVE TEMP CHA199STR1L/A L3

     FILE 'ZCAPLUS' ENTERED AT 08:40:02 ON 25 JUN 2008
L4              7 SEA ABB=ON  PLU=ON  L3

     FILE 'BEILSTEIN' ENTERED AT 08:40:14 ON 25 JUN 2008
L5              0 SEA SSS SAM L1
L6              3 SEA SSS FUL L1

     FILE 'WPIX' ENTERED AT 08:40:36 ON 25 JUN 2008
L7              0 SEA SSS SAM L1
L8             21 SEA SSS FUL L1
L9              5 SEA ABB=ON  PLU=ON  L8/DCR

     FILE 'ZCAPLUS' ENTERED AT 08:41:09 ON 25 JUN 2008
L10            19 SEA ABB=ON  PLU=ON  BROOKINGS D?/AU
L11          7394 SEA ABB=ON  PLU=ON  DAVIS J?/AU
L12            26 SEA ABB=ON  PLU=ON  LANGHAM B?/AU
L13            11 SEA ABB=ON  PLU=ON  L10 AND (L11 OR L12)
L14             9 SEA ABB=ON  PLU=ON  L11 AND L12
L15            11 SEA ABB=ON  PLU=ON  (L13 OR L14)

     FILE 'MEDLINE, EMBASE, BIOSIS, WPIX' ENTERED AT 08:43:37 ON 25 JUN 2008
L16            13 SEA ABB=ON  PLU=ON  L15

     FILE 'ZCAPLUS' ENTERED AT 08:45:09 ON 25 JUN 2008
                  D STAT QUE L15

     FILE 'MEDLINE, EMBASE, BIOSIS, WPIX' ENTERED AT 08:45:23 ON 25 JUN 2008
                  D STAT QUE L16

     FILE 'ZCAPLUS, MEDLINE, EMBASE, BIOSIS, WPIX' ENTERED AT 08:45:33 ON 25
     JUN 2008
L17            12 DUP REM L15 L16 (12 DUPLICATES REMOVED)
                       ANSWERS '1-11' FROM FILE ZCAPLUS
                       ANSWER '12' FROM FILE BIOSIS
                  D IBIB ABS L17 1-11
                  D IALL L17 12

     FILE 'REGISTRY' ENTERED AT 08:46:11 ON 25 JUN 2008

     FILE 'ZCAPLUS' ENTERED AT 08:46:14 ON 25 JUN 2008
                  D STAT QUE L4

     FILE 'BEILSTEIN' ENTERED AT 08:46:33 ON 25 JUN 2008
                  D STAT QUE L6

     FILE 'WPIX' ENTERED AT 08:46:42 ON 25 JUN 2008
```

```
              D STAT QUE L9

     FILE 'ZCAPLUS, BEILSTEIN, WPIX' ENTERED AT 08:46:52 ON 25 JUN 2008
L18          10 DUP REM L4 L6 L9 (5 DUPLICATES REMOVED)
                    ANSWERS '1-7' FROM FILE ZCAPLUS
                    ANSWERS '8-10' FROM FILE BEILSTEIN
              D IBIB ABS HITSTR L18 1-7
              D IDE ALLREF L18 8-10


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   23 JUN 2008  HIGHEST RN 1030103-54-8
     DICTIONARY FILE UPDATES:  23 JUN 2008  HIGHEST RN 1030103-54-8

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/support/stngen/stndoc/properties.html

     FILE ZCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS is
     strictly prohibited.

     FILE COVERS 1907 - 25 Jun 2008  VOL 148 ISS 26
     FILE LAST UPDATED: 24 Jun 2008  (20080624/ED)

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

       This file contains CAS Registry Numbers for easy and accurate
       substance identification.

     FILE BEILSTEIN
     FILE LAST UPDATED ON April 1, 2008

     FILE COVERS 1771 TO 2008.
      FILE CONTAINS 10,322,808  SUBSTANCES

     >>>PLEASE NOTE: Reaction Data and substance data are stored in
```

```
    separate documents and can not be searched together in one query.
    Reaction data for BEILSTEIN compounds may be displayed
    immediately with the display codes PRE (preparations) and REA
    (reactions).  A substance answer set retrieved after the search
    for a chemical name, a compounds with available reaction
    information by combining with PRE/FA, REA/FA or more generally
    with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
    between a BEILSTEIN compound and belonging reactions. For mo
    detailed reaction searches BRNs can be searched as reaction
    partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE  <<<

********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.              *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE        *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                      *
* FOR PRICE INFORMATION SEE HELP COST                              *
********************************************************************

>>> Price change as of January 1st, 2008: Connect Time and Structure
    Search fees re-introduced. See NEWS and HELP COST <<<

FILE WPIX
FILE LAST UPDATED:                          24 JUN 2008   <20080624/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE:     200840      <200840/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.1 million chemical structures in DCR <<<

>>> IPC Reform backfile reclassifications have been loaded to the end of
    March 2008. No update date (UP) has been created for the
    reclassified documents, but they can be identified by
    20060101/UPIC and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC,
    20071130/UPIC and 20080401/UPIC.
    ECLA reclassifications to April and US national classifications to
    the end of January 2008 have also been loaded. Update dates
    20080401/UPEC and /UPNC have been assigned to these. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomsonreuters.com/support/patents/coverage/latestupdate

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0710.p

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

>>> Please note that the COPYRIGHT notification has changed <<<


FILE MEDLINE
 FILE LAST UPDATED: 24 Jun 2008 (20080624/UP).  FILE COVERS 1949 TO DATE.

  MEDLINE has been updated with the National Library of Medicine's
  revised 2008 MeSH terms.  See HELP RLOAD for details.
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

FILE EMBASE
FILE COVERS 1974 TO 24 Jun 2008 (20080624/ED)

EMBASE was reloaded on March 30, 2008.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE codes as part of the EMTREE thesaurus in EMBASE. Please update your current-awareness alerts (SDIs) if they contain EMTREE codes.

For further assistance, please contact your local helpdesk.

FILE BIOSIS
FILE COVERS 1926 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 18 June 2008 (20080618/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

=>
Uploading L1.str



chain nodes :
10 12 13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
2-10 7-14 8-12 12-13 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 2-10 3-4 4-5 5-6 5-7 6-9 7-8 7-14 8-9 8-12 12-13 14-15

```
Connectivity :
10:1 E exact RC ring/chain  13:1 E exact RC ring/chain
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
12:CLASS  13:CLASS  14:CLASS  15:Atom
Generic attributes :
15:
Saturation             : Unsaturated
```